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ABSTRACT 
 TRIM5α is one of the best characterized anti-viral restriction factors and works 
specifically to inhibit the lifecycle of retroviruses. Following fusion of a retrovirus with its 
target cell, TRIM5α binds directly to the retroviral capsid, a proteinaceous core that 
houses the viral genome. Upon capsid recognition, TRIM5α forms a hexameric lattice 
around the retroviral capsid and initiates its antiviral activities, which include: (1) 
inhibition of viral infection; (2) inhibition of viral reverse transcription; (3) disassembly of 
the capsid; and (4), activation of innate signaling pathways. Importantly, the formation of 
this assembly also activates the E3 ubiquitin ligase function of TRIM5α. Ubiquitin 
modification is associated with directing substrates to particular cellular pathways. We 
and others have previously shown that TRIM5α spontaneously forms assemblies known 
as cytoplasmic bodies in cells, and these bodies colocalize with proteins involved in the 
cellular degradative pathway of autophagy. The autophagy pathway and its association 
with other TRIM proteins has been implicated in serval models of pathogen clearance, 
and therefore we hypothesized that autophagy may play a critical role in the function of 
TRIM5α as a retroviral restriction factor. The goal of this dissertation is to define the 
molecular interactions required for the association of TRIM5 proteins with autophagy 
effectors and to delineate the roles of ubiquitination and autophagy in retroviral 
restriction by TRIM5α. We first assessed the contribution of the autophagy pathway to 
the restriction of retroviral infection or reverse transcription by TRIM5α. We 
demonstrated that, when the autophagy factors ATG5 or Beclin1 are depleted in human 
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cell lines, the restriction of N-MLV by human TRIM5α, and HIV-1 by Rhesus macaque 
TRIM5α and owl monkey TRIM-Cyp is preserved. These data indicate that autophagy 
machinery is not required for retroviral restriction by TRIM5 proteins. However, given 
TRIM5α’s activity as a ubiquitin ligase, we wanted to further probe the ubiquitin-
dependent steps during retroviral restriction. We generated fusion proteins in which the 
catalytic domain of different deubiquitinase (DUb) enzymes, with different specificities 
for polyubiquitated linkages, was fused to the N-terminal RING domain of Rhesus 
macaque TRIM5α. Using these fusion proteins as tools, we assessed the role of 
ubiquitination in restriction and the degree to which specific types of ubiquitination are 
required for the association of TRIM5α with autophagic proteins. We determined that 
K63-linked ubiquitination by TRIM5α is critical for its association with autophagosome 
membranes. In the absence of K63-specific ubiquitin ligase activity, TRIM5α forms a 
stable association with the capsid, allowing reverse transcription to proceed, however, 
infection is still blocked. These data favor a model whereby the formation of a TRIM5α 
assembly around a capsid is sufficient to inhibit infection. Further, while the ubiquitin 
ligase activity of TRIM5α is needed to inhibit reverse transcription, recruitment of 
autophagic effectors is not required for restriction of infection or reverse transcription. 
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CHAPTER ONE 
REVIEW OF LITERATURE 
HIV-1 Pathogenesis 
Despite the advent of Highly Active Anti-Retroviral Therapy (HAART), infection 
with Human Immunodeficiency Virus-1 (HIV-1) continues to be a significant healthcare 
burden worldwide, as 40,000 Americans and ~2 million people worldwide become 
infected with this virus annually [1]. Furthermore, there are currently nearly 40 million 
people worldwide living with HIV-1 infection [2], and this prevalence continues to rise as 
people are living longer with HIV-1 infection due to the increasing availability of HAART 
[3, 4]. Encouragingly, the number of deaths associated with HIV and Acquired 
Immunodeficiency Syndrome (AIDS) has decreased in recent years [3]. 
 HIV-1 was identified as the causative agent of AIDS in the 1980s [5-7]. The 
epidemic arose from the cross-species transmission of simian immunodeficiency 
viruses found in African primates to humans [8]. The lineage of HIV-1 can be traced to 
four different subgroups, based on their proposed species of origin: Groups M, N, O, 
which were transmitted from chimpanzees; and Group P, which was transmitted from 
gorillas [3]. Group M is responsible for 48% of infections worldwide and is considered 
the cause of the global epidemic [9]. A related virus, HIV-2, was transmitted to humans 
from sooty mangabey monkeys, and although this virus causes similar clinical 
symptoms as HIV-1, it is considered to be less pathogenic because it is less 
transmissible and disease progression is slower [3, 8].  
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HIV-1 primarily targets CD4+ T lymphocytes, although other cells bearing the 
CD4 marker, including macrophages, monocytes, and dendritic cells, can also be 
targets of infection [3]. HIV-1 is predominantly transmitted via sexual or percutaneous 
routes, and mucosal transmission represents the major (80%) route of infection [10, 11]. 
A mixture of quasispecies of virus, representing defective viruses, less fit viruses, and 
competent viruses, are typically present in the blood or mucosal sites [12]. However, in 
most cases, a single virus is responsible for transmission and productive infection, and 
this virus is known as the Transmitted Founder virus [8, 12, 13]. Early replication of the 
Transmitted Founder virus is associated with an induction of cytokines and chemokines 
and the opportunity for the virus to infect more cells. CD8+ T cells are critical during the 
early stages of infection, as they kill infected cells and facilitate other arms of the innate 
and adaptive immune response [14]. Unfortunately, the development of the adaptive 
immune response is sometimes associated with the mutation of epitopes, such as in the 
viral envelope glycoprotein, which drives immune escape [14]. Approximately 20% of 
infected individuals are able to produce broadly neutralizing antibodies that are able to 
neutralize a number of HIV-1 subtypes. In infected individuals, however, these 
antibodies do not lead to clearance, but rather act as drivers of escape mutations [15]. 
Furthermore, over time, many individuals experience a progressive loss of function of 
HIV-1 specific CD8+ T cells, termed exhaustion [16]. Exhaustion is associated with a 
loss of effector function and the expression of one or several inhibitory receptors, 
particularly PD-1, on the cell surface [16]. 
Clinically, HIV-1 infection is associated with a loss of CD4+ T cells that occurs as 
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a result of toxicity of infection or the immune response [17]. If infection is left untreated, 
the loss of CD4+ T cells is associated with the development of opportunistic infections 
and significant mortality [3]. However, regardless of treatment status, HIV-1 infection is 
also associated with inflammation and general immune activation. This activation is 
thought to be driven by activation of plasmacytoid dendritic cells, which produce copious 
amounts of type I IFN [18]. Importantly, this heightened inflammation contributes to a 
number of HIV-related complications and comorbidities, including cardiovascular 
disease, cancer, neurological disease, and liver disease [3]. 
Latency 
Despite the success of antiretroviral therapy in suppressing viral loads, the virus 
almost universally rebounds after treatment interruption [3]. As a result, HIV-1 infected 
individuals are generally required to remain under therapy for life in order to maintain 
low viral loads and avoid the adverse sequelae associated with continued viral 
replication. One of the perplexing questions in the field, and the major burden to a cure, 
is determining where and how the virus remains latent during the treatment phase. This 
latent reservoir is the subject of significant ongoing research. Latency in the HIV field 
refers to the integration of virus’s DNA into a host’s DNA without the production of virus 
[3]. The precise identity of cells forming the latent reservoir is still under debate, with 
studies implicating resting, memory, and naïve T cells as potentially composing the 
reservoir [19-21]. Several hypotheses have been suggested to explain the 
establishment of the latent reservoir, and these hypotheses largely focus on events or 
conditions that keep the virus in a transcriptionally silent state, such as integration of the 
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viral DNA into transcriptionally inactive chromatin; epigenetic control of the HIV-1 
promoter; the absence of transcription factors, such as NFκB, which drive the 
expression of viral genes; or low expression of the viral protein Tat, which is needed for 
efficient transcription of the viral genome [3, 8, 22]. Furthermore, latently infected cells 
are known to persist long term and are thus a critical barrier to a cure. 
 Therefore, there is significant research in the field to identify methods of 
eradicating the latent reservoir. One of the prevailing strategies involves activating the 
cells to allow for transcriptionally silent viruses to become expressed (“Shock”) and 
subsequently be targeted by antiretroviral drugs or immune responses (“Kill”) [3, 8]. To 
date, many studies have investigated drugs that are able to reactivate the expression of 
latent viruses, including chromatin remodeling agents and NFκB activators [3]. 
However, there is limited data supporting the ability of these reactivation efforts to 
reverse latency in vivo [3, 8]. 
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Figure 1. The Clinical Course of HIV-1 Infection. The course of HIV-1 infection can 
be divided into acute and chronic stages. The acute phase is associated with a high 
viral load in the blood and the dissemination of the virus to different sites in the body, as 
well as a decline in CD4+ T cell numbers. Over time, the chronic phase of infection 
develops and is associated with the development of viral escape mutants and increased 
pathological sequelae affecting multiple organ systems. Over time, AIDS develops as 
the CD4+ T cell count is further depleted. The introduction of HAART therapy can 
forestall many of the complications associated with late stages of disease, though the 
virus remains present in latently infected cells. Reprinted with permission from [23]. 
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Figure 2. The Structure of HIV-1. Depicted here is the structure of the mature HIV-1 
virion. HIV is an enveloped RNA virus. The viral envelope, derived from the host cells, is 
studded with viral Env glycoproteins, which facilitate fusion to the target cell. Encased 
within the envelope is the core. The core consists of the capsid, a proteinaceous conical 
structure housing the viral genomic RNA and viral proteins, such as integrase, reverse 
transcriptase, and viral accessory proteins. Reprinted with permission from [24]. 
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Figure 3. The Life Cycle of HIV-1. Upon fusion, HIV-1 undergoes reverse transcription 
of its RNA genome into DNA, uncoating of the capsid, and trafficking to the nucleus, 
where it integrates into the host genome. HIV-1 RNA, consisting of genomic RNA and 
messenger RNA, is transcribed and exported to the cytoplasm, where they can be 
utilized in the synthesis of viral proteins and the generation of the next generation of 
virions. Many of these steps can be inhibited by cellular proteins knowns as restriction 
factors (yellow boxes). However, these restriction factors in turn can be antagonized by 
viral proteins (blue circles). Reprinted with permission from [25]. 
 
HIV-1 Lifecycle 
The lifecycle of HIV-1 (Figures 2 and 3) begins with the binding of the virus’s 
envelope glycoprotein, gp120, to the CD4 receptor and coreceptors, such as the 
chemokine receptors CXCR4 or CCR5, on target cells [26]. Subsequently, the virus 
fuses with the host cell, and the viral capsid enters into the target cytoplasm. The capsid 
is a proteinaceous conical core containing the viral genome and viral proteins, such as 
integrase, reverse transcriptase, and viral accessory proteins (Figure 2). The term 
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capsid refers to the cone-shaped unit composed of individual CA monomers, while the 
core refers to the capsid structure along with its associated genome and viral proteins 
[27]. Upon entry, the capsid engages the cellular microtubule network to move through 
the cell and traffic toward the nucleus [27, 28].  
During the core’s movement through the cytoplasm, the single-stranded RNA 
genome of HIV-1 is converted into double-stranded DNA via the enzyme reverse 
transcriptase within the core [29]. Reverse transcription initiates a process known as 
uncoating, whereby the capsid undergoes a regulated process of disassembly or loss of 
integrity, though the details of this are under considerable debate [27, 30-32]. 
Importantly, some amount of CA remains associated with the reverse-transcribed 
genome (known at the Pre-Integration Complex, or PIC), as numerous studies have 
identified host cellular factors that bind to the capsid and that are critical for trafficking of 
the PIC across the Nuclear Pore Complex (NPC) and protection of the genome from 
cytoplasmic sensors [27, 33, 34]. However, the capsid itself can also function as a 
Pathogen Associated Molecular Pattern (PAMP) and be recognized and sensed by 
cellular factors, namely TRIM5α [35]. Given these interactions with cellular factors, it 
would be advantageous for the virus to mutate its capsid in order to avoid cellular 
recognition. However, the capsid is considered “genetically fragile”, as mutations within 
it are associated with impaired reverse transcription, trafficking, and integration, and 
have been associated with innate sensing [27, 33, 34, 36, 37]. Therefore, the centrality 
of the capsid to HIV-1’s life cycle and its genetic vulnerability make it an important target 
for antiviral approaches, and understanding factors that bind to and target the capsid 
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could give important insight into the next generation of treatment approaches to target 
HIV-1 infection. 
  Upon reaching the nucleus, the PIC engages cellular factors at the nuclear pore 
and enters into the nucleus. There are several models of how the PIC translocates into 
the nucleus, concerning whether an intact core or a partially disassembled core is the 
species that reaches the nuclear pore complex [27]. Nevertheless, several studies have 
identified CA proteins in the nucleus, which could be relevant for optimal nuclear import 
and integration site selection [27, 38, 39]. Integration of the HIV-1 reverse transcribed 
DNA into the host DNA is mediated by the viral enzyme integrase, which is associated 
with the PIC.  
Once integrated, the virus’s genome can be transcribed to produce both viral 
genomic RNA as well as mRNA [40]. Transcription relies on cellular transcription 
factors, namely NFκB and NFAT, and occurs relatively inefficiently until expression of 
the viral protein tat, which drives efficient viral transcription [22]. With Tat present, 
several different types of viral transcripts are produced (Figure 4), and these include: 
unspliced RNA, which comprises the genomic RNA and Gag or GagPol precursors 
(discussed more, below); singly spliced RNA, which encodes the messages for the 
Envelope glycoprotein (Env) and the accessory proteins Vif, Vpr, Vpu; or fully spliced 
RNA, which encodes messages for Tat, Rev, and Nef [22]. 
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Figure 4. Transcription of HIV-1 RNA. Transcription of HIV-1 RNA produces several 
species, due to differential splicing. These include: full length unspliced RNA (~9 kb), 
which comprises the genomic RNA and Gag or GagPol precursors; singly spliced RNA 
(~4 kb), which encodes the messages for the Envelope glycoprotein (Env) and the 
accessory proteins Vif, Vpr, Vpu; or completely spliced RNA (~2 kb), which encodes 
messages for Tat, Rev, and Nef.  Reprinted with permission from [41]. 
 
Subsequently the viral protein Rev facilitates the transport of viral RNAs to the 
cytoplasm where they can be used to produce viral proteins and the next generation of 
virions [22, 40]. Translation of viral RNA produces several products. The Gag 
polyprotein precursor, which encodes the matrix (MA), capsid (CA), nucleocapsid (NC) 
and p6 domains, is produced by translation of the full-length viral RNA [40]. In addition, 
a frameshift during the translation of the Gag precursor produces GagPol, which in turn 
encodes MA, CA, NC, protease, reverse transcriptase, and integrase proteins [40]. 
Newly synthesized Gag binds to and recruits viral genomic RNA as it is exported from 
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the nucleus to the cytoplasm, and in turn this complex, along with newly synthesized 
envelope glycoprotein (Env), is concentrated at the plasma membrane [40]. 
Subsequently, the assembling virus engages members of the cellular endosomal sorting 
complex required for transport (ESCRT) pathway to facilitate budding and release of the 
viral particle [40]. Once the virus has been released, the protease is activated and can 
cleave the Gag precursor protein into its constituent proteins [40].  
During this time, the individual CA monomers assemble into the fullerene cone 
structure of the capsid, in the process encapsidating the viral RNA, integrase, reverse 
transcriptase, and some accessory proteins [27]. The capsid is comprised of 
approximately 1,500 CA monomers that spontaneous assemble into hexamers 
(predominantly) and pentamers to make up the structure of the cone [27, 42]. It is this 
mature core that is released into the cytoplasm during the subsequent round of 
infection.   
Antiretroviral Therapy 
The development of combinatorial antiretroviral therapy regimens was essential 
for control of the HIV-1 epidemic and is responsible for the decreased mortality 
associated with infection [43]. Currently, over 25 drugs have been developed to target 
various aspects of the HIV-1 life cycle, and importantly, these drugs are utilized in 
combinations to limit the potential development of drug resistance [3]. Standard 
regimens include several reverse transcription inhibitors, a protease inhibitor, and an 
integrase inhibitor [3]. The reverse transcription inhibitors fall into one of two classes: 
nucleoside reverse transcription inhibitors (NRTI), which inhibit reverse transcription by 
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acting as a “chain terminator” of DNA synthesis; and non-nucleoside reverse 
transcription inhibitors (NNRTI), which bind to and inhibit the reverse transcriptase 
enzyme directly [44, 45].  Significantly, the onset of therapy produces a substantial 
decrease in plasma viral load, usually to levels below the limit of detection of common 
laboratory tests [3]. In contrast, the rebound of CD4+ T cells is variable among patients, 
and the extent of CD4+ T cell recovery, which is critical to forestall the onset of 
HIV/AIDS related complications, such as the development of opportunistic infections,  
could be related to the timing of initiation of treatment following acute infection [3].  
Restriction Factors 
Through the course of completing its life cycle, HIV-1 potentially interacts with 
many different host proteins, and over the course some of these host proteins evolved 
to specifically inhibit one or more steps in the viral life cycle. These factors can 
collectively be termed restriction factors (Figure 3). Restriction factors were first 
described in the context of defining the cellular factors that protected mice from infection 
by murine leukemia virus, and the identification of Fv1 in the 1960s (discussed in more 
detail, below) opened the door to look for cellular proteins that inhibit viral replication. 
Since then, a number of specifically-anti-HIV restriction factors have been 
characterized. Generally, restriction factors represent different classes of proteins and 
act through different mechanisms, although they share some common characteristics. 
Some common features include: inducibility by interferon; they can be antagonized by 
viral proteins or accessory proteins; and they may display evidence of positive selection, 
suggesting co-evolution with the targeted pathogen over time [46]. 
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APOBEC3 Proteins. 
Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-like 3 
(APOBEC3) proteins are widely expressed cellular proteins that utilize their cytidine 
deaminase activity to convert cytidine residues in RNA or DNA into uridines, which in 
turn introduces mutations in the resulting sequence [46]. APOBEC3 proteins are 
particularly deleterious to HIV-1 because the APOBEC3 proteins can be packaged into 
assembled virions. Upon fusion and release of the core into the cytoplasm, APOBEC3 
proteins can promote the development of mutations in the newly reverse-transcribing 
DNA [47-50]. This hypermutated DNA often severely compromises viral fitness, and as 
such, the HIV-1 accessory protein Vif evolved to specifically counteract APOBEC3. Vif 
acts by binding to APOBEC3 proteins and promoting their ubiquitination by a cellular 
ubiquitin ligase, ultimately leading to the proteasomal degradation of APOBEC3 [51]. 
 
SAMHD1. 
SAM Domain and HD Domain-Containing Protein 1 (SAMHD1) is a cytoplasmic 
dNTPase that acts to regulate the pool of free dNTPs in the cytoplasm, which in turn 
limits the ability of HIV-1 to reverse transcribe its genome [52-54]. Importantly, SAMHD1 
can be antagonized by accessory proteins from HIV-2 or SIV, namely Vpr and Vpx  [54]. 
However HIV-1 does not encode an antagonist to SAMHD1, and this thought to explain 
the relative inability of HIV-1 to infect macrophages compared to its HIV-2 and SIV 
counterparts [54], as macrophages are known to possess a much lower concentration 
of cytoplasmic dNTPs available for reverse transcription compared to that found in CD4+ 
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T cells [55]. 
MxB. 
Myxovirus Resistance Protein B (MxB) is another interferon-inducible inhibitor of 
HIV-1 infection. It interacts with the assembled capsid structure, rather than CA 
monomers [56-59]. As Mx2 is a relatively newly discovered restriction factor, much is 
unknown about its mechanism of action. It is thought to act after viral reverse 
transcription but before integration of the viral DNA, and prevailing models propose that 
Mx2 interferes with nuclear import of the PIC [60]. 
Tetherin. 
Tetherin was identified as an interferon-inducible cellular factor that inhibits the 
release of assembled virions from the producer cell [61, 62]. Tetherin is known to 
anchor into the plasma membrane, however the precise mechanisms by which it block 
viral release are still under debate [46]. Importantly, through the action of tetherin, 
viruses are thwarted from release and are instead internalized into endosomes for 
degradation [46, 62]. The HIV-1 protein Vpu antagonizes the effects of tetherin, though 
its mechanism of action is also still under debate [46, 61, 62].  
Capsid Binding Restriction Factors: Fv1, Ref1, and Lv1 
The discovery of factors that are able to bind to the retroviral capsid began in the 
1960s, as researchers investigated the factors responsible for the susceptibility of mice 
to infection by Murine Leukemia Virus (MLV) [63]. Eventually, Friend virus 1 (Fv1) was 
identified as the cellular factor that protects mice from MLV infection [64-67]. Two alleles 
of Fv1, denoted Fv1n and Fv1b, were found to be responsible for conferring resistance 
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to B-tropic MVL (B-MLV) and N-tropic MLV (N-MLV), respectively [64-67]. Sensitivity to 
Fv1-mediated restriction was mapped to the capsid protein of MLV [68, 69], as the 
capsids of B-MLV and N-MLV differ by a single amino acid [68]. Furthermore, restriction 
of infection was found to occur after the completion of viral reverse transcription but 
before integration into the host’s DNA [70]. Pre-integration Complexes (PICs) isolated 
from cells expressing Fv1 were found to be competent for integration in vitro, 
suggesting that Fv1 arrests PICs that are on a productive path to infection [71]. In 
addition, researchers found that restriction by Fv1 could be abrogated by the addition of 
increasing amounts of restriction-sensitive virus, suggesting that the activity of this 
factor could be saturated [72, 73]. In 1996, the gene encoding Fv1 was identified [74, 
75], and it was found that this gene was related to the Gag protein of an endogenous 
retrovirus present in the mouse genome [76]. 
 Following the discovery and characterization of Fv1, researchers sought to 
identify similar cellular factors that conferred resistance to retroviral infection of non-
murine cells. In 2000, a factor known as Ref1 was identified, and it was found to protect 
mammalian cells, including human cells, from infection by N-MLV but not B-MLV [77]. 
Intriguingly, Ref1 shared some properties with Fv1, namely, that its target mapped to 
the capsid of N-MLV,  and its activity could be saturated by the addition of increasing 
amounts of restriction-sensitive virus [77]. However, in contrast to Fv1, Ref1 restricts 
retroviral infection prior to the completion of reverse transcription [77]. 
 Several years after the discovery of Ref1, researchers identified a similar factor, 
termed Lv1, which is responsible for the restriction of lentiviral infection [78-81]. As 
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Ref1, restriction by Lv1 mapped to the lentiviral capsid, could be saturated, and 
occurred prior to the completion of reverse transcription [78-81]. Eventually, the 
discovery of TRIM5α, a restriction factor that inhibits HIV-1 infection in Old World 
Monkeys, was identified to be a species-specific variant of Lv1 and Ref1 [82-86]. 
TRIM Family of Proteins 
The Tripartite Motif (TRIM) family is a diverse group of cellular proteins that 
function in a variety of cellular pathways (Figure 5). Over 80 TRIM proteins have been 
identified, and they have been implicated in functions as diverse as regulating cell cycle 
progression, autophagy, innate immunity, signaling, pathogen clearance, and the 
degradation of proteins [87]. The members of the TRIM family are distinguished by the 
presence of the RBCC motif, consisting of: a RING domain, which acts as an E3 ligase; 
one or two Bbox domains, and a Coiled-coil domain, which are important for self-
association and higher-order assembly [87, 88]. The functions of these domains will be 
discussed below. 
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Figure 5. The TRIM Family of Proteins. TRIM proteins share the Tripartite Motif, 
consisting of a RING, one or two Bbox, and Coiled-coil domains. The different members 
of this family are distinguished by the presence of different C-terminal domains. 
Reprinted with permission from [88].  
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Domains of TRIM Proteins 
RING Domain. 
Most TRIM proteins possess an N-terminal Really Interesting New Gene (RING) 
domain, which functions as an E3 ligase to catalyze the addition of ubiquitin (most 
commonly), small ubiquitin-like modifier (SUMO), or Interferon-stimulated proteins of 15 
kDa (ISG15) to substrates [89]. The activity of the RING domain can be regulated by 
assembly mediated by the other domains, and this activity can influence the overall 
function of the particular TRIM protein [87, 90]. 
Bbox and Coiled-coil Domains. 
Both the Bbox and Coiled-coil domains of TRIM proteins are critical for their self-
association and the formation of higher-order assemblies [90]. There are two types of 
Bbox domains, type 1 and type 2, which differ in their ability to coordinate zinc ions [91]. 
Most TRIM proteins possess the type 2 Bbox (Bbox2), whereas others possess both 
type 1 and type 2 [90]. The Coiled-coil domain is critical for dimerization among TRIM 
proteins. This domain is generally helical in structure, and structural studies of several 
TRIM proteins, including TRIM5α, TRIM20, TRIM25, and TRIM69, demonstrate that the 
dimerization of these TRIM proteins involves the formation of an antiparallel dimer 
mediated by the CC domain [87, 90]. 
C-terminal Domain of TRIM Proteins. 
The C-terminal domains of TRIM proteins are variable and differentiate the 
members of this family from one another. The C-terminal domains are important for the 
binding of TRIM proteins to other factors, and they can be involved with directing TRIM 
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proteins to different subcellular localizations [87, 90]. TRIM proteins are subdivided into 
11 groups based on their C-terminal domains, the most common of which is the 
PRYSPRY domain (also known as B30.2), which can be found in over 30 TRIM proteins 
[90, 92]. 
Discovery of TRIM5α 
For many years, scientists observed that certain primate species were naturally 
resistant to infection by HIV-1, and many groups sought to identify the determinant(s) 
responsible for this resistance[77, 79-81, 93]. In 2004, a screen from a cDNA library 
prepared from Rhesus macaque fibroblasts identified TRIM5α as the cellular factor that 
protects Old World monkey cells from infection by HIV-1 [85]. Similar to Ref1 and Lv1, 
TRIM5α targets the HIV-1 capsid, its activity can be saturated, and restriction occurs 
before reverse transcription [85]. Subsequent studies concluded that Ref1 and Lv1 are 
species-specific variants of TRIM5α [82, 83]. Importantly, TRIM5 proteins possess the 
ability to restrict retroviruses from different species (Figure 6), and different primate 
orthologues of TRIM5 were shown to have variable restriction efficiency of different 
retroviruses [94, 95].  
 While TRIM5α and Fv1 are both retroviral restriction factors, they have several 
important differences in their structure and function. First, Fv1 and TRIM5α proteins are 
very different at the primary sequence level, and Fv1 does not have a RING or BBox2 
domain [63]. Nevertheless, both TRIM5α and Fv1 possess a Coiled-coil domain, which 
facilitates multimerization, as well as a C-terminal domain responsible for binding to the 
retroviral capsid [96-99]. Also, while restriction of retroviral infection is a conserved 
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property between TRIM5α proteins and Fv1, the timing of this restriction occurs either 
before or after reverse transcription [63]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Specifies Specificity of Retroviral Restriction by Different TRIM5 
Proteins. TRIM5 proteins demonstrate species-specific restriction of different 
retroviruses. Depicted here is the restriction efficacy of different TRIM5 proteins against 
retroviruses, classified as strong restriction (++), mildly restriction (+) or no restriction (-). 
Reprinted with permission from [63]. 
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Figure 7. Domains and Assembly of TRIM5α. (A) The domain structure of TRIM5α, 
discussed below. TRIM5α forms an antiparallel dimer (putative structure in (B)). TRIM5α 
further assembles into a hexagonal lattice formation, a model of which is depicted in 
(C). Reprinted with permission from [100].  
22 
   
 
 
TRIM5α: Domain Structure and Function 
RING Domain. 
TRIM5α possesses the RBCC motif characteristic of this family. The RING 
domain of TRIM5α proteins functions as an E3 ubiquitin ligase. Early investigations of 
the function of the RING domain were complicated by the observation that mutation of 
the catalytic cysteine residue in the RING domain produced unstable or large, non-
functional aggregates of protein [98, 101]. Nevertheless, later studies found that the 
function of the RING domain is activated in the context of higher-order assembly of 
TRIM5α proteins [102], and that the RING domain catalyzes the autoubiquitination of 
TRIM5α itself [103], as well as the synthesis of free, unanchored polyubiquitin chains 
[35, 103].  
Bbox and Coiled-coil Domains. 
As with other TRIM proteins, the Bbox2 and Coiled-coil domains of TRIM5α are 
necessary for the formation of higher-order assemblies [104, 105]. Furthermore, 
dimerization of TRIM5α is mediated by the Coiled-coil domain, which forms an 
antiparallel dimer (Figure 7B) [106, 107], and is required for restriction [98, 108]. 
C-terminal PRYSPRY Domain of TRIM5α Proteins. 
TRIM5α proteins possess a C-terminal PRYSPRY (hereafter referred to as 
SPRY) domain, which confers restriction specificity for different retroviruses [109-113]. 
Early experiments investigating the saturation of restriction factors identified that the 
retroviral capsid protein is the target of restriction factor binding. However, individual 
TRIM5α proteins demonstrate low affinity for binding to individual CA monomers [114]. 
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In contrast, this low affinity binding can be overcome by the multimerization of TRIM5α 
proteins around the capsid, which thereby fosters a higher avidity interaction between 
TRIM5α and the capsid [108, 115-117]. Furthermore, this low affinity interaction 
between TRIM5α proteins and the capsid offers the advantage of allowing TRIM5α to 
restrict multiple retroviruses, as well as to readily accommodate changes in the 
retroviral capsid [115]. Owl monkeys express a variation of TRIM5α in which the SPRY 
domain is replaced by a Cyclophilin A (Cyp) domain [118, 119], producing a restriction 
factor known as TRIM-Cyp. As CypA is known to bind to the HIV-1 capsid [120], TRIM-
Cyp remains a potent restrictor of HIV-1 infection. 
 The binding of TRIM5α proteins to the retroviral capsid is a critical determinant of 
restriction, and several groups have identified regions in the SPRY domain, particularly 
a 13-amino acid stretch in the variable loops of the SPRY domain, that are under strong 
positive selection [121, 122]. This observation supports the hypothesis that TRIM5α is 
constantly undergoing evolution in order to restrict retroviruses. Furthermore, although 
human TRIM5α is less potent at restricting HIV-1 infection compared to Rhesus 
macaque TRIM5α, it is likely that human TRIM5α evolved to restrict an ancient 
retrovirus for which its specificity was better suited [121, 123]. Notably, introduction of a 
single amino acid substitution at position 332 in human TRIM5α is sufficient to impart 
potent anti-HIV-1 restriction capabilities to human TRIM5α [124]. This observation 
supports the hypothesis that human TRIM5α is not grossly incapable of restriction of 
HIV-1, and that strategies may exist to enhance the anti-HIV-1 restriction activities of 
human TRIM5α. 
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Higher Order Assembly of TRIM5α 
With the cooperation of its Bbox2 and Coiled-coil domains, TRIM5α readily forms 
higher-order assemblies structured as a hexagonal lattice (Figure 7C, 8) [115-117, 125]. 
This hexagonal lattice formation was observed to occur spontaneously in vitro (Figure 
8), suggesting the formation of such an assembly is an “intrinsic property” of TRIM5α 
proteins [115]. However, lattice formation forms much more readily in the presence of in 
vitro assembled viral capsid assemblies, suggesting the capsid may act as a template 
for seeding the formation of the TRIM5α lattice [115]. Furthermore, the TRIM5α lattice 
matches the symmetry of the viral capsid lattice (Figure 8) [115]. Finally, formation of 
the TRIM5α lattice facilitates dimerization of RING domains on neighboring TRIM5α 
monomers within the lattice, and this arrangement thereby activates the E3 ligase 
function of the RING domains [102]. Activation of the RING domain has important 
implications for TRIM5α’s anti-retroviral functions, and these effects will be examined in 
more detail below. Importantly, it is clear that assembly of the TRIM5α lattice around the 
retroviral capsid is a critical aspect of downstream restriction functions. 
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Figure 8. Assembly of TRIM5α around the Retroviral Capsid Lattice. (A) TRIM5α 
spontaneously forms a hexagonal lattice structure in vitro on assembled CA assemblies. 
(B) TRIM5α assembles a lattice around the viral capsid, matching the symmetry of the 
viral capsid. Reprinted with permission from [115]. 
 
Ubiquitin and Ubiquitin Ligases 
Ubiquitin is a 76-amino acid protein that can be covalently or noncovalently 
attached to substrates, and this modification is often the signal to direct substrates to 
particular cellular pathways [126, 127]. The addition of ubiquitin to a substrate involves 
the coordinated action of several enzymes. A particular E1 enzyme, known as the 
ubiquitin activating enzyme, binds to ubiquitin that can be found freely in the cell [87]. 
Subsequently, E2 and E3 enzymes, which are known as ubiquitin conjugating and 
ligating enzymes respectively, catalyze the addition of the ubiquitin protein to a 
particular lysine residue in the substrate [87]. Ubiquitin has seven internal lysines 
(residues 6, 11, 27, 29, 33, 48, and 63), and these residues, along with the N-terminal 
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methionine of ubiquitin, can be targets of ubiquitination themselves, thereby producing 
polyubiquitin linkages [87, 128]. The polyubiquitin linkages can be anchored to a 
particular protein substrate, or they can be unanchored [129, 130]. Importantly, different 
polyubiquitin linkages are associated with different cellular fates. K48 and K63-linked 
polyubiquitin chains are the most prevalent, representing approximately 80% of all 
ubiquitin linkages observed in mammalian cells [131]. K48-linked polyubiquitin chains 
are canonically associated with directing substrates to the proteasome for degradation, 
while K63-linked polyubiquitin modification is associated with endosomal trafficking, 
intracellular signaling, and DNA repair [126-128, 132-134]. Intriguingly, substrates 
bearing K48 and K63-linked polyubiquitin chains have been shown to bind to 
proteasome components with similar affinities in vitro [135], and proteins modified by 
K63-linked polyubiquitin chains have been demonstrated to be proteasome targets in 
vitro [136]. Nevertheless, there is little evidence that K63-linked polyubiquitination is a 
signal for proteasomal degradation in vivo. 
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Figure 9. Overview of Ubiquitin and Polyubiuquitin Linkages. Ubiquitin contains 
seven internal lysine residues (K, shown in red in the bottom panel) that can be 
modified by ubiquitin themselves, producing polyubiquitin chains. The structure and 
most common function of these linkages is listed in the figure. Reprinted with 
permission from  [137]. 
 
Proteasomes and Proteasomal Degradation 
The proteasome is one of the major cellular degradative pathways (Figure 10). 
The eukaryotic proteasome is a 2.5 megadalton complex consisting of several important 
domains [138]. The central part of the proteasome complex is composed of a hollow 
20S core, within which resides the proteolytic enzymes that are responsible for the 
degradation of protein substrates [138]. In addition, the central region of the proteasome 
also contains a 19S regulatory region, which houses ubiquitin-binding receptors that 
bind to ubiquitinated substrates and direct them into the degradative region of the 
proteasome [135, 138]. The ubiquitin-binding receptors within the proteasome bind to 
the ubiquitin tag, after which the proteasome machinery directs the substrate into the 
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core, processively unfolding the substrate as it moves through the core [139, 140]. From 
there, the unfolded protein is sensitive to degradation by the proteolytic enzymes 
present within the 20S core [139, 140]. The ubiquitin itself is cleaved away from the 
substrate via proteasome-associated deubiquitinase enzymes (DUBs) so that it can be 
recycled [141]. 
 Degradation of substrates via the proteasome is classically associated with K48-
linked polyubiquitination. Interestingly, several studies have reported that the ubiquitin-
binding receptors present within the 19S region of the proteasome bind to both K48 and 
K63-linked polyubiquitin chains with equal affinity in vitro [135, 138]. However, another 
study found that the processivity of the proteasome varies based on the polyubitination 
modifications on a substrate, with K48 or mixed polyubiquitination linkages promoting 
greater processivity of the proteasome compared to K63-linked polyubiquitin chains 
[134]. One proposed model to explain the role of ubiquitin chains in influencing 
proteasomal processivity is that K48-linked polyubiquitin chains switches the 
proteasome to an activated state, which facilitates substrate degradation [134]. 
 Generally, K63-linked polyubiquitin chains are not associated with directing 
substrates to the proteasome for degradation in vivo [142, 143]. Several models have 
been proposed to explain why this linkage may not be preferred for proteasomal 
degradation. First, cellular factors may occlude binding the of K63-linked polyubiquitin 
chains to the proteasome [138]. One study found that members of the ESCRT 
((Endosomal Sorting Complex Required for Transport) family of proteins binds to 
proteins marked by K63-linked polyubiquitin chains and blocks their ability to bind to 
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proteasomal components [138]. Second, proteasomal deubiquitinase enzymes may 
cleave K63-linked polyubiquitin chains from substrates, thereby promoting their release 
from the 19S region prior to degradation [138, 141]. Finally, it is possible that cellular 
factors may selectively enhance the recruitment and binding of substrates marked with 
K48-linked polyubiquitin chains to components of the proteasome, thereby promoting 
their efficient degradation [138, 141]. One exception to this model is that K63-linked 
ubiquitin modification to a substrate has been shown to, in some cases, act as a seed 
for the generation of mixed-linkage K48- and K63- linked polyubiquitin chains, which in 
turn can be directed to the proteasome for degradation [144]. 
 
 
 
Figure 10. Schematic of the Eukaryotic Proteasome. Ubiquitinated substrates 
engage the proteasome either directly (a) or via adaptor proteins (b). Subsequently, the 
proteasome degrades these substrates, and ubiquitin is recycled via proteasome 
associated deubiquitinases (DUBs). Reprinted with permission from [145].  
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Autophagy and TRIM Proteins 
 Macroautophagy (hereafter autophagy) is a conserved mechanism of 
degradation of cytoplasmic substrates and can be induced by a number of stimuli, 
including starvation, stress, or invasion by pathogens [146, 147]. It initiates with the de 
novo formation of a double-membraned vesicle, termed the autophagosome, around a 
particular substrate, such as cellular proteins, organelles, or even pathogens, and this 
action, in turn, sequesters the contents from the cytoplasm [146, 147]. A number of 
cellular proteins are involved in the formation of the autophagosome. Studies of 
autophagy in yeast have identified at least thirty-one autophagy related proteins (Atg 
proteins) as being involved in autophagosome formation and maturation [147]. In the 
past, autophagy was considered to be a relatively nonselective degradative mechanism, 
with the proteasome being considered the more selective cellular degradative pathway 
[147]. However, emerging evidence identifies adaptor proteins, including members of 
the TRIM family, may be responsible for the selective targeting of substrates to the 
autophagosome for degradation [146]. One well-characterized adaptor protein is 
SQSTM1/p62. p62 is known to be able to bind to the autophagosome membrane 
marker LC3, and importantly, it is also able to bind to ubiquitinated proteins [147-149]. 
Once formed, the autophagosome is delivered to the lysosome, where degradative 
enzymes within the lysosome can degrade or recycle the contents of the 
autophagosome [147]. 
 Recent studies have highlighted the importance of TRIM proteins in autophagic 
clearance [150]. The proposed role of TRIMs in autophagy first involves the recognition 
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of particular targets by TRIM proteins. Subsequently, the TRIM proteins may assemble 
and recruit autophagy machinery to promote the formation of the autophagosome and 
downstream clearance [150]. For example, TRIM20 and TRIM21 have been shown to 
bind to components of the inflammasome pathway and the type I interferon response, 
respectively, and subsequently, the TRIMs recruit autophagic machinery to these 
targets to promote their degradation [151].  
Mechanisms of Restriction by TRIM5α 
 Similar to Fv1, TRIM5α is able to restrict retroviral infection. However, early 
studies of TRIM5α quickly identified important differences between the restriction 
mechanisms of these two factors. Upon fusion of the virus with the host cell, the capsid 
undergoes a regulated program of gradual or partial disassembly known as uncoating, 
although the precise mechanisms of this process are still under debate [27]. However, 
the consensus in the field is that reverse transcription of the viral genome is closely tied 
to uncoating [27, 30-32]. Capsids that are too stable or too labile demonstrate impaired 
reverse transcription and replication [36], and therefore, the precise timing of reverse 
transcription and uncoating is a critical aspect of retroviral infection. Binding of TRIM5α 
and its orthologues to the retroviral capsid occurs within minutes after viral fusion [152, 
153]. TRIM5α readily forms a lattice structure around the retroviral capsid [115-117], 
and subsequently, TRIM5α is able to promote the premature disassembly of the capsid 
[154, 155]. This disassembly event was uncovered as researchers determined that 
upon infection, pelletable capsids, which represent the higher-order structure of the 
conical core, were unable to be recovered from cells expressing a restriction-competent 
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TRIM5α orthologue [155]. In cells expressing human TRIM5α, one observes a decrease 
in pelletable N-MLV capsid and a corresponding increase in soluble monomeric capsid 
(CA) protein [155]. In contrast, while cells expressing Rhesus macaque TRIM5α 
produced a similar decrease in pelletable HIV-1 capsid, an increase in soluble CA was 
difficult to detect due to the presence of pre-existing soluble CA in cytoplasm of cells 
[155]. Nevertheless, the loss of pelletable capsid was, in all cases, associated with a 
block to infection, and the implication was that disassembly of the capsid is a critical 
aspect of restriction by TRIM5α proteins [155].  
 Since then, a several groups have sought to determine the mechanism of how 
TRIM5α disrupts capsids, leading to their premature disassembly. One hypothesis was 
that following capsid binding, TRIM5α recruits the capsid and its associated viral 
components to cellular degradative machinery, such as the proteasome or autophagy 
pathways. Early investigations focused on the proteasome as having a central role in 
restriction because, in the presence of proteasome inhibitors such as MG132, the block 
to retroviral infection remains intact, but the block to reverse transcription is relieved 
[156, 157]. The reverse transcription products that accumulate in the presence of 
MG132 are competent for integration into DNA in vitro, indicating these products are on 
a productive path to infection [156]. Furthermore, in the presence of MG132, TRIM5α 
forms stabilized associations with capsids, and this has been observed by many groups 
in biochemical and imaging-based approaches [152, 155, 158]. These observations 
helped shape the hypothesis that TRIM5α could utilize the proteasome to promote the 
degradation of the capsid and its associated viral components; when the proteasome is 
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inhibited, the capsid is not destabilized, and reverse transcription can proceed, while the 
block to infectivity, measured as gene expression from an integrated provirus, remains 
[156, 157]. These data suggest that, similar to Fv1, restriction of reverse transcription is 
not critical for restriction of infection by TRIM5α [156-158]. Furthermore, these data 
suggest that TRIM5α has likely evolved multiple mechanisms to inhibit retroviral 
infection [77, 156-158].  
 Nevertheless, the observation that TRIM5α forms stabilized complexes with the 
capsid in the presence of proteasome inhibitors [152] suggested that the proteasome 
has some role in the destabilization and/or degradation of viral components. Two 
studies have observed colocalization between TRIM5α proteins and components of the 
proteasome [159, 160]. To determine if this association with proteasomes had any 
functional impact on TRIM5α’s restriction mechanism, one study tracked the fates of the 
capsid, integrase enzyme, and viral RNA, throughout infection in the presence or 
absence of MG132 [158]. The study found that during restriction, Rhesus macaque and 
human TRIM5α solubilize the capsid and viral RNA of HIV-1 and N-MLV, respectively 
[158]. However, in the presence of MG132, the core complex, containing the capsid, 
integrase, and viral RNA, is retained, and these cores are indistinguishable from 
unrestricted viral cores [158]. These studies concluded that the proteasome is required 
for disruption of the core but not restriction of infection [158]. Collectively, these studies 
suggest a two-step model of restriction by TRIM5α. In the first step, TRIM5α or its 
orthologues binds to the retroviral capsid, and this is sufficient to block infection. In the 
second step, which is sensitive to proteasome inhibitors, TRIM5α induces the 
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premature disassembly of the viral capsid and prevents the accumulation of reverse 
transcription products. 
 However, these studies raised key questions about the role of proteasomes in 
capsid destabilization, as proteasomes are more associated with the degradation of 
linear peptides rather than the consumption of a large complex, such as TRIM5α bound 
to a capsid. As an E3 ubiquitin ligase, TRIM5α promotes both its own autoubiquitination 
as well as the synthesis of unanchored K63-linked polyubiquitin chains [35, 103]. To 
date, no study has identified the capsid as being a substrate for ubiquitination by 
TRIM5α proteins [155, 158], however, it is possible that only a small portion of CA 
monomers could be ubiquitinated, which would be difficult to resolve by Western blot 
[158, 161]. However, another study found that expression of TRIM5α itself decreased in 
the presence of a restriction-sensitive virus, and this reduction in expression could be 
reversed in the presence of MG132 [162]. Notably, the reduction in expression of 
TRIM5α proteins was associated specifically with being in the presence of a restriction-
sensitive virus, as no reduction was observed in the context of an unrestricted virus 
[162]. These data suggested a possible connection between the degradation of TRIM5α 
proteins and their ability to restrict retroviruses. TRIM5α has a rapid turnover in cells 
(approximately 50-60 min) [163], and one hypothesis was that the degradation of the 
capsid is linked to TRIM5α’s turnover. However, cells expressing a RING domain 
mutant of TRIM5α with a longer half-life still maintained the ability to restrict infection, 
indicating that the fast turnover of TRIM5α proteins is not driving restriction of 
retroviruses [163]. Therefore, although there appears to be a step in restriction (the 
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inhibition of reverse transcription) that is sensitive to proteasome inhibitors, it is unclear 
whether proteasomal degradation per se is necessary for capsid disassembly.  
 Importantly, several pieces of evidence argue against the proteasome having a 
central role in capsid disassembly. First, TRIM5α proteins are known to bind to CA 
monomers with low affinity [114], and therefore it is unclear how this low affinity binding 
would transmit enough force to drive both TRIM5α and its bound capsid to the 
proteasome for degradation. In addition, proteasomal degradation is classically 
associated with K48- rather than K63-linked polyubiquitin chains, and it is therefore 
unclear how TRIM5α, which has been associated with the production of K63-linked 
polyubiquitin chains in vitro [103], is recruited to the proteasome for degradation. 
Previous studies have also interrogated autophagy and its role in TRIM5α-
mediated restriction. We have previously observed that TRIM5α associates with the 
autophagic adaptor protein p62/sequestosome1, and depletion of p62 by siRNA caused 
a reduction in retroviral restriction in cells expressing human TRIM5α (huTRIM5α) or 
Rhesus macaque TRIM5α (RhTRIM5α) [164] ; however, because the depletion of p62 
also reduced the expression level of TRIM5α, we could not conclude that p62 is directly 
required for the restriction of retroviruses by TRIM5α. However, two recent studies 
implicated autophagy in the clearance of HIV-1 by TRIM5α, proposing that after binding 
to the viral capsid, TRIM5α recruits autophagic machinery to degrade the virus within 
the lysosome [146, 165]. Although this observation appears to disagree with other 
studies suggesting a proteasome-dependent step in restriction, this apparent 
discordance might be explained by crosstalk between autophagic and proteasomal 
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pathways, which is known to occur in many contexts [166, 167], or by gross perturbation 
of ubiquitin homeostasis caused by pharmacological inhibition of the proteasome.    
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Figure 11. Proposed Models of Retroviral Restriction and Core Destabilization by 
TRIM5α. (A) (left side) During the HIV-1 lifecycle, the core is delivered to the cytoplasm 
of the target cell. The virus reverse transcribes is genome, uncoats its capsid, and 
traffics to the nucleus for integration. (right side) TRIM5α exists as diffuse proteins or 
aggregations called cytoplasmic bodies. During restriction, TRIM5α forms assemblies 
around the retroviral capsid (B), and in turn this assembly formation could be sufficient 
to inhibit infection. Alternatively, TRIM5α could engage the proteasome (C) or 
autophagosome (D) to destabilize capsids, which may or may not be important to block 
infection.   
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CHAPTER TWO 
MATERIALS AND METHODS 
Cells and Pharmaceuticals 
Expression plasmids for yellow fluorescent protein-tagged Rhesus macaque 
TRIM5α (YFP- RhTRIM5α) and hemagluttinin (HA)-tagged RhTRIM5α or TRIM-Cyp 
have been described previously [168, 169]. To quantify TRIM5α accumulation, a 
lentiviral plasmid (pLVX, Clontech) expressing human TRIM5α containing a C-terminal 
Firefly luciferase reporter gene was created. HeLa and TE671 cell lines were obtained 
from the American Type Culture Collection. THP-1 cells were obtained from the AIDS 
reagent repository. Wt and ATG5-/- Mouse Embryo Fibroblasts (MEFs) were generously 
provided by Noboru Mizushima (University of Tokyo). HeLa, TE671 and wt and ATG5 -/- 
MEFs were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS) (HyClone, Logan) UT, USA), 100 U/ml penicillin, 100 
µg/ml streptomycin, and 10 µg/ml ciprofloxacin. THP-1 cells were cultured in RPMI 
medium with identical FBS and antibiotics as above. Cells were maintained in the 
presence of 5% CO2 at 37°C. Bafilomycin A1 and MG132 (Cayman Chemical 
Company, Ann Arbor, Michigan, USA) were used at 100 nM and 1 µg/ml, respectively. 
Cyclohexamide was used at 20 µg/ml. Cyclosporine A (CsA; Sigma Aldrich) was used 
at a final concentration of 2.5 µM. 
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Cloning and Generation of Stable Cell Lines 
Stable expression of YFP-LC3 was achieved by cloning YFP-LC3, described 
previously [170], into a retroviral vector [21]. To generate stable cell lines, retrovirus was 
prepared by transfecting equal amounts of VSV-G, pCigB packaging plasmid, EXN 
YFP-LC3 into HEK293T cells. Viral supernatant was harvested 48 hrs post-transfection, 
filtered through 0.45 µm filters (Milipore), and applied to A549 cells. 48 hrs after 
transduction, G418 was added to the cells, and following selection, cells were collected 
for phenotypic analysis.  
Generation of deubiquitinase Rhesus-TRIM5α fusion proteins was performed as 
described previously [171]. Briefly, catalytically active and inactive deubiquitinase 
enzymes utilized in this study were: HSV-1 UL36 DUb (residues 15-260, [171, 172]); 
AMSH-LP (residues 265-436, a kind gift from the Fukai Lab, University of Tokyo, [173]); 
and OTUB1 (a kind gift from the lab of Wade Harper, (Addgene plasmid # 22551), 
mutation described in [174]). Each of these DUBs was cloned, in frame, into a pLVX 
Flag-Rhesus TRIM5α, in between the Flag-tag and a short linker sequence before the 
start codon of Rhesus TRIM5α, using SOEing PCR. To generate stable cell lines, 
lentivirus was prepared by transfecting equal amounts of VSV-G, psPAX2 (from Dr. 
Didier Trono, NIH AIDS Reagent Program, Cat. # 11348) [175], and the pLVX-DUB-
Rhesus TRIM5α constructs into HEK293T cells. Viral supernatant was harvested 48 hrs 
post-transfection, filtered through 0.45 µm filters (Milipore), and applied to TE671, HeLa, 
or A549 cells. 48 hrs after transduction, puromycin was added to the cells, and following 
selection, cells were collected for phenotypic analysis. 
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Generation of Knockout Cells Using CRISPR/Cas9 Genome Editing 
Indicated knockout TE671, HeLa, and A549 cell lines were generated using 
LentiCRISPRv2 (Addgene plasmid #52961), a gift from Dr. Feng Zhang [176]. Guide 
sequences were generated using the CRISPR design tool at http://www.crispr.mit.edu 
or were taken from available guide sequences from the Genome-scale CRISPR 
knockout (GeCKO2) library [176]. The following oligos were annealed and cloned into 
LentiCRISPRv2 (puromycin resistance) or LentiCRISPRv2-Hygromycin (which we 
designed):  oligo targeting ATG5: 5’- CACCGGATGGACAGTTGCACACACT-3’; oligo 
targeting Beclin1: 5’- CACCGATCTGCGAGAGACACCATCC-3’; oligo targeting 
p62/SQSTM1: 5’- CACCGTGAAACACGGACACTTCGGG-3’; oligo targeting control 
sequence: 5’-CACCGGCACTACCAGAGCTAACTCA-3’. Lentivirus was prepared by 
transfecting equal amounts of VSV-G, psPAX2 (from Dr. Didier Trono, NIH AIDS 
Reagent Program, Cat. # 11348) [175, 177], and LentiCRISPRv2 (containing the guide 
RNA of interest) into HEK293T cells. Viral supernatant was harvested 48 hrs post-
transfection, filtered through 0.45 µm filters (Milipore), and applied to TE671, HeLa, or 
A549 cells. 48 hrs after transduction, puromycin or hygromycin was added to the cells, 
and following selection, cells were collected for knockout assessment by Western blot 
and phenotypic analysis. 
Flow Cytometry 
 For viral infectivity assessment by flow cytometry, equivalent numbers of 
indicated cell lines were plated in 24-well plates. Dilutions of viral supernatant were 
applied to the cells, after which the cells were subject to spinoculation (1200 x g, 2 hrs 
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at 13°C). For experiments involving cells expressing TRIM-Cyp, cyclosporine A (final 
concentration of 2.5 µM) or DMSO was added to the cells concurrently with viral 
supernatant. Following spinoculation, media was subsequently changed, and after 48 
hrs, the cells were harvested and fixed in a 1% formaldehyde-PBS solution for flow 
cytometric analysis. Percent infectivity was determined by measuring the proportion of 
GFP-positive cells in the FITC channel for 10,000 events per sample, using a FACS 
Canto II flow cytometer (Becton Dickinson, San Jose, CA, USA). 
Immunofluorescence Microscopy 
Cells were allowed to adhere to fibronectin-treated glass coverslips and fixed 
with 3.7% formaldehyde (Polysciences) in 0.1 M PIPES [piperazine-N,N'-bis(2-
ethanesulfonic acid)], pH 6.8. Cells were permeabilized with 0.1% saponin, 10% normal 
donkey serum, 0.01% sodium azide in PBS. We used the following primary antibodies: 
rabbit anti-LC3b (Sigma-Aldrich, St. Louis, MO, USA); mouse anti-LAMP2A (BD 
Pharmigen, San Diego, CA, USA); rabbit anti-Flag (Sigma-Aldrich, St. Louis, MO, USA), 
and mouse ant- HIV-1 p24 (Santa Cruz) . Primary antibodies were labeled with 
fluorophore-conjugated donkey anti-mouse or anti-rabbit antibody (Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA, USA). Images were collected 
with a DeltaVision microscope (Applied Precision, Issaquah, WA, USA) equipped with a 
digital camera (CoolSNAP HQ; Photometrics, Tucson, AZ, USA), using a 1.4-numerical 
aperture (NA) 100x objective lens, and were deconvolved with SoftWoRx software 
(Applied Precision, Issaquah, WA, USA). 
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Image Analysis 
20-30 Z-stack images were acquired using identical acquisition parameters. 
Deconvolved images were analyzed using Imaris software (Bitplane). For analysis of 
colocalization between YFP-RhTRIM5α and autophagy markers, surfaces were 
generated around YFP-RhTRIM5α. Then, the maximum fluorescence intensities of 
LC3b and LAMP2A within each surface were quantified. Background fluorescence 
intensities were calculated and used to set LC3b and LAMP2A intensity thresholds. For 
analysis of colocalization between Flag-RhTRIM5α or the deubiquitinase-fusion proteins 
and YFP-LC3b and/or p24, surfaces were generated around Flag (Figure 12). Maximum 
fluorescence intensities of YFP-LC3b and p24 within each surface were quantified. Both 
graphing and statistics calculations were performed in Prism (Graphpad Software, Inc). 
As indicated on each graph, data is presented as the mean and SEM, and significance 
was determined by Student’s t-test or ANOVA, as indicated. 
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Figure 12. Image Analysis Schematic. To analyze images, a particular channel of 
interest is selected (B) and, and we design three dimension surfaces around the puncta 
within the given channel (C, D). Then, one can determine the intensity of the other 
channels within each of these surfaces in order to assess the degree of colocalization. 
The surfaces are designed with an algorithm and applied to all images. 
siRNA Transfections 
Transcripts for several macroautophagy factors were targeted using the following 
siRNAs: ATG5 (Santa Cruz Cat. No. sc-41445), Beclin1 (Santa Cruz Cat. No. sc-
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29797), p62/SQSTM1 (Santa Cruz Cat. No.  sc-29679), and Control siRNA (Santa Cruz 
Cat. No. sc-37007). 300,000 TE671 cells were plated in 6-well plates and were 
transfected with 30 nM of the indicated siRNAs twice over a 48-hour period. The 
siRNAs were transfected using Lipofectamine 2000 (Life Technologies, Cat. No. 
11668027, Grand Island, NY, USA), according to manufacturer’s instructions.  Whole-
cell lysates were prepared 72 hrs following the second transfection, as described above. 
Proteins were separated via SDS-PAGE and transferred onto nitrocellulose 
membranes. Membranes were probed with α-Atg5 (Novus, Cat. No NB110-53818), α-
Beclin1 (Cell Signaling, Cat. No. 3738), α-p62/SQSTM1 (Cell Signaling, Cat. No. 
7695S), and anti-β-actin and anti-β-tubulin antibodies. Secondary antibodies conjugated 
to HRP (Thermo Fisher Scientific, Waltham, MA, USA) were used where necessary, 
and antibody complexes were detected using SuperSignal West Femto 
chemiluminescent substrate (Thermo Fisher Scientific, Waltham, MA, USA). 
Chemiluminescence was detected using a UVP EC3 imaging system (UVP LLC Upland, 
CA, USA). 
Virus Generation and Titering 
HIV and MLV reporter virus were prepared as described previously [164]. Briefly, 
HIV-1 reporter virus was produced by polyethylenimine [26] transfection of 293T cells 
with 10 μg of VSV-G and 15 μg of the proviral construct R7ΔEnvGFP, in which the Nef 
gene was replaced with GFP. MLV reporter virus was produced by PEI transfection of 
293T cells with equal amounts of VSV-G, pCigN or pCigB packaging plasmid (for N-
MLV and B-MLV generation, respectively), and GFP reporter vector.  Virus was 
45 
 
 
 
harvested as previously described [178]. MLV was titered on CRFK cells to normalize 
viral input in infectivity studies, as described previously [156]. R7ΔEnvGFP was titered 
as described previously [177] 
Quantitative Real-Time PCR for Viral RT Products 
Quantitation of viral RT products was performed as previously described [156, 
157]. Briefly, equivalent numbers of indicated cells were seeded in 12-well plates. Cells 
were infected with indicated virus, and they were subsequently incubated for 18 hrs at 
37°C.  Genomic DNA was harvested using a DNeasy tissue kit (Qiagen, Valencia, CA, 
USA) according to the manufacturer's instructions and digested with 1 unit/µl DpnI (New 
England Biolabs, Ipswich, MA, USA) for 4 hrs at 37°C to remove residual plasmid DNA. 
Real-time PCR was performed with SYBR green PCR reagent (Applied Biosystems, 
Carlsbad, California, USA) using primers for late RT, GFP and GAPDH. Dilutions of 
proviral plasmid and GAPDH (10-fold) were used to generate standard curves. Samples 
were normalized to 10 ng of total cellular DNA or GAPDH standards. 
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CHAPTER THREE 
HYPOTHESIS AND SPECIFIC AIMS 
Host cell restriction factors are a class of proteins that inhibit viral replication by blocking 
the ability of a virus to complete its life cycle. TRIM5α is one of the best characterized 
anti-viral restriction factors. Members of the TRIM family of proteins are defined by 
having a tripartite motif consisting of an N-terminal RING domain, which functions as an 
E3 ubiquitin ligase; one or two B-box domains; and a Coiled-coil domain. TRIM5α is 
distinguished from other members of this family by its C-terminal SPRY domain, which 
allows TRIM5 proteins to directly bind to the retroviral capsid, a proteinaceous core that 
houses the viral genome [85, 155]. Upon capsid recognition, the B-box and Coiled-coil 
domains, which are critical for self-assembly among many TRIM family members [97, 
108, 117, 179], facilitate assembly of TRIM5 to form a multimeric lattice surrounding the 
viral core [115, 116, 180]. Furthermore, higher-order assembly of TRIM5 also activates 
the E3 ubiquitin ligase function of the RING domain [102]. Through the formation of this 
multimeric assembly, TRIM5 is able to initiate its antiviral activities, which include: (1) 
inhibition of viral infection; (2) inhibition of viral reverse transcription; disassembly of the 
capsid; and (4), synthesis of K63-linked ubiquitin chains that activate innate signaling 
pathways and induce an "antiviral state" for the cell [35, 103, 155, 157]. While the 
inhibition of viral infection by TRIM5α is well-characterized, the precise mechanism by 
which TRIM5α promotes the degradation of the retroviral capsid remains unknown. 
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Several groups, including our own, have determined that there is step in restriction that 
is sensitive to proteasome inhibitors, as treatment with proteasome inhibitors allows 
reverse transcription to proceed, though infection is still blocked, suggesting a 
proteasome dependent step in the restriction process [152, 156, 157, 160, 162]. 
However, several recent high profile studies have implicated autophagy as having a 
central role in retroviral restriction by TRIM5α [146, 165]. Thus the relationship between 
the autophagic and proteasomal degradation pathways and the functions of TRIM5α 
remains unresolved. 
Autophagy is a conserved cellular process whereby cargoes such as proteins or 
organelles are sequestered into a double-membraned vesicle and transported to the 
lysosome for degradation or recycling. We and others have previously shown that 
TRIM5α spontaneously forms assemblies known as cytoplasmic bodies in cells, and 
these bodies colocalize with proteins involved in autophagy, including the adaptor 
molecule p62/SQSTM1 and the autophagosome membrane marker LC3b [164, 181]. 
Furthermore, we and others have also demonstrated that the turnover of TRIM5α is 
partially autophagy-dependent [146, 181]. Intriguingly, autophagy has also been 
implicated in pathogen clearance. For example, a recent study described how cells 
employ autophagy to clear Salmonella infection by tagging the invasive bacteria with 
ubiquitin [182, 183]. These ubiquitinated bacteria are then recognized by p62/SQSTM1 
and directed to autophagosomes for degradation [182, 183]. Similarly, another recent 
study highlighted how infection with certain RNA viruses triggers the activation of 
TRIM23, which in turn activates p62/SQSTM1 and promotes the induction of autophagy 
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[160, 184]. Taken together, these observations suggest that the autophagic pathway 
may play a critical role in the function of TRIM5α as a restriction factor. The goal of this 
proposal is to define the molecular interactions required for the association of TRIM5 
proteins with autophagy effectors and to delineate the roles of ubiquitination and 
autophagy in TRIM5α restriction. 
Aim 1: Determine if TRIM5 proteins require autophagy effectors for the restriction 
of retroviral infection and reverse transcription. To test the requirement of 
autophagy in restriction, we examined the ability of TRIM5α to restrict retroviral infection 
in cells depleted of autophagic mediators ATG5, Beclin1, and p62. In all cases, 
restriction of retroviral infection and reverse transcription by human TRIM5α, Rhesus 
macaque TRIM5α, and owl monkey TRIM-Cyp remained potent in cells depleted of 
these autophagic effectors by siRNA knockdown or CRISPR/Cas9 genome editing 
[181].  
Aim 2: Determine if the ubiquitin ligase activity of TRIM5α is required for its 
association with autophagy effectors and its ability to restrict retroviral infection 
and reverse transcription. We generated fusion proteins in which the catalytic domain 
of different deubiquitinase (DUb) enzymes, with different specificities for 
polyubiquitinated linkages, was fused to the N-terminal RING domain of Rhesus 
TRIM5α. Using these fusion proteins as tools, we sought to assess the role of 
ubiquitination in: (A) the restriction of infection and reverse transcription; (B) 
destabilization of the capsid core; and (C) the degree to which specific types of 
ubiquitination are required for the association of TRIM5α with autophagic proteins. 
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CHAPTER FOUR 
RESULTS 
Inhibition of Autophagy Alters the Cellular Localization of Rhesus TRIM5α 
A novel characteristic of the TRIM family of proteins is their intrinsic ability to form 
higher order assemblies, and in the case of TRIM5α, this activity is essential for the 
ability of the protein to act as a retroviral restriction factor [169]. Normally, RhTRIM5α 
localizes to both small, discrete cytoplasmic puncta, termed cytoplasmic bodies [85] and 
a diffuse pool of cytoplasmic protein that is capable of forming cytoplasmic bodies de 
novo around individual virions [152, 168]. We previously observed that cytoplasmic 
bodies of RhTRIM5α colocalize with the autophagic adaptor protein p62 [164]. In 
contrast, previous studies have observed that treatment of cells stably expressing 
RhTRIM5α with MG132, a proteasome inhibitor, drives the protein to form cytoplasmic 
bodies that are larger in size than normal bodies [157]. Therefore, to study the effects of 
autophagic or proteasomal inhibition on the cellular localization of YFP-RhTRIM5α, 
HeLa cells stably expressing YFP-RhTRIM5α were treated with BafA1, which prevents 
hydrogen flux through the ATPase present on lysosomal and endosomal membranes 
[185], or MG132 for 18 hrs, after which the abundance of YFP-RhTRIM5α in cells was 
quantified. As shown in Figure 13, inhibition of autophagy by BafA1 altered the 
localization of TRIM5α, resulting in the accumulation of more numerous cytoplasmic 
bodies than observed in untreated cells (Fig. 13A and C), while treatment with MG132 
recapitulated previously published findings (Fig. 13B). These observations were 
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validated by quantitative image analysis to characterize YFP-RhTRIM5α localization in 
data sets obtained from the individual treatment groups. BafA1 treatment produced a 
substantial increase in the number of cytoplasmic bodies per cell (Fig. 13D), compared 
to both untreated and MG132 treated cells. Therefore, BafA1 treatment alters the 
subcellular localization of RhTRIM5α, resulting in more numerous cytoplasmic bodies, 
consistent with these bodies being autophagosomal structures destined for clearance 
via lysosomal degradation pathways. 
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Figure 13. Subcellular Localization of YFP-RhTRIM5α Changes in the Presence of 
BafA1 and MG132. (A-C) HeLa cells stably expressing YFP-RhTRIM5α were seeded 
onto fibronectin treated coverslips for 18 hrs. Cells were left untreated or treated with 
BafA1 or MG132 during this time. Cells were subsequently fixed and stained with DAPI. 
Z-stack images were collected with a DeltaVision microscope equipped with a digital 
camera using a 1.4-numerical aperture (NA) 100× objective lens, and were deconvolved 
with SoftWoRx deconvolution software. Individual channel images were superimposed 
to create the merged panels. Images of cells left untreated (A), treated with MG132 (B), 
or treated with BafA1 (C) are presented. Images are representative of at least three 
experiments. (D) To quantify the number of RhTRIM5α cytoplasmic bodies in each 
treatment group, 20 images were taken per treatment under identical acquisition 
parameters. Each image was analyzed using Imaris imaging software. The mean and 
standard error of the mean [186] are highlighted in red. *, P<0.0001. 
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Rhesus TRIM5α Colocalizes with Autophagic Markers LC3b and LAMP2A 
following BafA1 Treatment 
Our observation that treatment with BafA1 increases the accumulation of YFP-
RhTRIM5α suggested that TRIM5α is degraded by an autophagic pathway. 
Accordingly, if YFP-RhTRIM5α is degraded by autophagy, then we would expect that 
the cytoplasmic bodies of YFP-rhTRIM5α, which accumulate upon BafA1 treatment, to 
colocalize with markers of autophagy. To test this hypothesis, we utilized 
immunofluorescence microscopy to quantify the degree of colocalization between YFP-
RhTRIM5α and LC3b, a common marker of autophagosomes, and Lysosomal 
Associated Membrane Protein 2A (LAMP2A) in HeLa cells. In untreated cells, a subset 
of YFP-RhTRIM5α puncta was observed to colocalize with LC3b and LAMP2A (Fig. 
14A and B), with approximately 30% of the YFP-rhTRIM5α cytoplasmic puncta being 
positive for at least one of these markers (Fig. 14C). However, after 6 hrs of treatment 
with BafA1, the colocalization of YFP-RhTRIM5α with both markers substantially 
increased (Fig 14A and B), such that ~68% of puncta were positive for one of the two 
markers, and approximately 35% were positive for both LC3b and LAMP2A (Fig. 14C). 
These data suggest that YFP-RhTRIM5α is rapidly turned over by autophagic 
degradation. When autophagy is inhibited by BafA1, YFP-RhTRIM5α that has been 
targeted for degradation accumulates in compartments containing LC3b and LAMP2A. 
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Figure 14. RhTRIM5α Colocalizes with the Autophagy Markers LC3b and LAMP2. 
(A and B) HeLa cells stably expressing YFP-RhTRIM5α were seeded onto fibronectin 
treated coverslips. Cells were left untreated or treated with BafA1 for 6 hrs. Cells were 
fixed, permeabilized and costained with rabbit anti-LC3b (A) and mouse anti-LAMP2A 
(B) and DAPI. Representative images of cells left untreated or treated with BafA1 are 
presented. (C) To quantify the number of RhTRIM5α cytoplasmic bodies that were 
positive for LC3b or LAMP2A following each treatment, 20 Z-stack images were taken 
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per treatment, under identical acquisition parameters. Imaris imaging software was used 
to identify YFP-RhTRIM5α puncta, and the maximum LC3b and LAMP2A staining 
intensity in each surface was calculated and plotted. Percentages indicate the number 
of RhTRIM5α cytoplasmic bodies that are positive for LAMP2A, LC3b, both, or neither. 
Images are representative of at least three independent experiments. 
 
Depletion of Autophagic Effectors Does Not Relieve N-MLV Restriction by Human 
TRIM5α 
The above studies provide evidence to suggest that YFP-RhTRIM5α is degraded by an 
autophagic pathway. We next asked if the depletion of key macroautophagy effector 
proteins was able to perturb TRIM5α-mediated retroviral restriction. To this end, we 
assessed retroviral restriction in human TE671 cells, which endogenously express 
human TRIM5α and therefore potently restrict N-tropic murine leukemia virus (N-MLV) 
but are permissive to infection by B-tropic MLV (B-MLV) [84]. TE671 cells were 
transfected with siRNAs targeting ATG5, Beclin1 or p62, and the infectivity of N-MLV 
and B-MLV was assessed. As expected, N-MLV infection was potently inhibited 
compared to B-MLV infection in TE671 cells subject to control siRNA transfection (Fig. 
15B). Notably, knockdown of ATG5, Beclin1 or p62 did not relieve the restriction of N-
MLV infection (Fig. 15B), suggesting that these effectors of macroautophagy are not 
required for the restriction of N-MLV by huTRIM5α.  
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Figure 15. Depletion of Autophagic Mediators by siRNA Does Not Affect N-MLV 
Restriction by HuTRIM5α. (A) TE671 cells were transfected with siRNAs targeting 
ATG5, Beclin1, or p62, or a control siRNA. Expression of the indicated proteins was 
detected by Western blot 72 hrs post-transfection. (B) TE671 cells transfected with 
siRNAs targeting ATG5, Beclin1, or p62, or a control siRNA were collected at 72 hrs 
post-transfection. Equal numbers of siRNA-transfected cells were plated and infected 
with equivalent titers of VSV-G pseudotyped N-MLV or B-MLV. Cells were harvested 48 
hrs after infection and infectivity, signified by the percentage of GFP-positive cells, was 
measured by flow cytometry. The data shown here is representative of three 
independent experiments.  
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To confirm and extend this observation, we generated TE671 cells in which the 
ATG5 gene or the Beclin1 gene were disrupted using CRISPR/Cas9 genome editing 
(Fig. 16C and E). Similar to our findings in cells depleted of ATG5 or Beclin1 by siRNA, 
we observed no relief of TRIM5α-mediated restriction of N-MLV in TE671 cells in which 
ATG5 or Beclin1 was knocked out (Fig. 16D and F).  
To determine if ATG5 or Beclin1-dependent macroautophagy are required for the 
restriction of reverse transcription by TRIM5α, we also measured reverse transcription 
products generated by N-MLV and B-MLV in these cells. As we and others have 
previously observed, reverse transcription by N-MLV was reduced, relative to reverse 
transcription by B-MLV, in unmodified TE671 cells (Fig. 16G and H). Importantly, the 
restriction of N-MLV reverse transcription, relative to that of B-MLV, was preserved in 
cells depleted of ATG5 or Beclin1 (Fig. 16G and H). These data demonstrate that 
perturbation of macroautophagy does not abrogate restriction of retroviral infection or 
reverse transcription by endogenously expressed huTRIM5α. 
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Figure 16. Depletion of Autophagic Mediators by CRISPR/Cas9 Genome Editing 
Does Not Affect N-MLV Restriction by HuTRIM5α. TE671 cells were depleted of 
ATG5 (C) or Beclin1 (E), using CRISPR/Cas9 genome editing, and protein expression 
of ATG5 in wild-type and knockout cells was confirmed by Western blot. Infectivity of 
VSV-G pseudotyped N-MLV or B-MLV in wild-type or ATG5 (D) or Beclin1 (F) knockout 
TE671 cells was assayed. The data shown here is representative of three independent 
experiments. Wild-type or ATG5 (G) or Beclin1 (H) knockout TE671 cells were infected 
with equivalent titers of VSV-G pseudotyped N-MLV or B-MLV, and viral reverse 
transcription products were measured. Three independent experiments were 
conducted, and the amount of viral DNA detected in each experiment was normalized to 
the wild-type untransduced sample infected with B-MLV of that experiment. Error bars 
represent the standard deviation of the relative number of viral DNA products detected 
across three independent experiments.  
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Depletion of Autophagic Effectors Does Not Relieve HIV-1 Restriction by Rhesus 
TRIM5α or Owl Monkey TRIM-Cyp 
We next assessed if autophagic adaptors are also required for the restriction of HIV-1 
by RhTRIM5α and owl monkey TRIM-Cyp. We generated HeLa cell lines in which ATG5 
or Beclin1 were disrupted by CRISPR-Cas9 genome editing (Fig. 17A and C and 18A). 
When challenged with HIV-1, we observed extensive infection in wild-type HeLa cells 
and in HeLa cells depleted of ATG5 or Beclin1 (Fig. 17B and D). In contrast, when wild-
type and ATG5 or Beclin1-depleted HeLa cells were transduced to stably express 
RhTRIM5α, these cells potently restricted HIV-1 infection relative to their untransduced 
counterparts (Fig. 17B and D). Analogous results were obtained in ATG5 knockout 
mouse embryonic fibroblasts (not shown).  
 We next examined the ability of RhTRIM5α to inhibit the formation of HIV-1 
reverse transcription products in cells depleted of macroautophagy factors. In 
untransduced ATG5 and Beclin1 knockout HeLa cells, reverse transcription was 
reduced relative to unmodified HeLa cells, consistent with the reduction in infectivity 
observed in these cells (Fig. 17E and F).  In each case, however, potent restriction of 
reverse transcription was observed in cells expressing rhTRIM5α, compared to their 
untransduced counterparts.  
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Figure 17. Depletion of Autophagic Mediators Does Not Affect the Restriction of 
HIV-1 by RhTRIM5α. HeLa cells depleted of ATG5 (A) or Beclin1 (C) by CRISPR/Cas9 
genome editing were transduced to stably express HA-tagged rhTRIM5α (or left 
untransduced). Wild-type, ATG5 (B), or Beclin1 (D) knockout HeLa cells, either with or 
without exogenous RhTRIM5α expression, were infected with a VSV-G pseudotyped 
HIV-1 reporter virus, and infectivity was measured by flow cytometry. The data shown 
here is representative of three independent experiments. (E) Wild-type, ATG5 (E), or 
Beclin1 (F) knockout HeLa cells, either with or without exogenous RhTRIM5α 
expression, were infected with equal titers of VSV-G pseudotyped HIV-1, and viral 
reverse transcription products were measured by quantitative PCR. For each sample, 
viral DNA, as measured by the number of GFP reporter copies detected, was 
normalized to the amount of GAPDH observed in parallel samples. Three independent 
experiments were conducted, and the amount of viral DNA detected in each experiment 
was normalized to the wild-type untransduced sample of that experiment. Error bars 
represent the standard deviation of the relative number of viral DNA products detected 
across three independent experiments. 
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Furthermore, we observed similar restriction in wild-type and ATG5 or Beclin1 
knockout HeLa cells stably expressing owl monkey TRIM-Cyp, compared to 
untransduced cells (Fig. 18B). Notably, relief of restriction by TRIM-Cyp was only 
observed when infection was carried out in the presence of cyclosporine A (CsA), which 
is known to inhibit the interaction of TRIM-Cyp with the capsid of HIV-1 (Fig. 18B) [119, 
153]. Collectively these data reinforce that the restriction of HIV-1 infection by both 
RhTRIM5α and owl monkey TRIM-Cyp is independent of macroautophagy adaptors 
ATG5 and Beclin1. Furthermore, RhTRIM5α does not require ATG5 or Beclin1 to 
complete restriction of HIV-1 infection or reverse transcription. 
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Figure 18. Depletion of ATG5 Does Not Affect the Restriction of HIV-1 by Owl 
Monkey TRIM-Cyp. (A) HeLa cells depleted of ATG5 by CRISPR/Cas9 genome editing 
were transduced to stably express HA-tagged owl monkey TRIM-Cyp (or left 
untransduced). (B) Wild-type or ATG5 knockout HeLa cells, either with or without 
exogenous owl monkey TRIM-Cyp expression (as depicted in (A)) were infected with a 
VSV-G pseudotyped HIV-1 reporter virus either in the absence or presence of 
cyclosporine A (- or + CsA, respectively). Cells were harvested 48 hrs after infection and 
infectivity, signified by the percentage of GFP-positive cells, was measured by flow 
cytometry. The data shown here is representative of three independent experiments. 
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Inhibition of Ubiquitination Produces Stable Association of TRIM5α and HIV-1 in 
THP-1 and A549 Cells 
Initial studies investigating the mechanism of restriction of retroviral infection by 
TRIM5 proteins determined that TRIM5 causes a destabilization of the retroviral capsid 
[155, 187], and early models invoked cellular degradative machinery, such as the 
proteasome or autophagy pathways, as being critical mediators of this destabilization. 
Previous studies identified that in the presence of the proteasome inhibitor MG132,  
Rhesus TRIM5α is unable to restrict HIV-1 reverse transcription, although infection is 
still inhibited [156, 157]. In addition, Rhesus TRIM5α forms stabilized complexes with 
HIV-1 virions in the presence of MG132 [152, 155, 158]. Intriguingly, these complexes 
stain positively for ubiquitin [152], possibly indicating a role for ubiquitin or ubiquitination 
in TRIM5α’s anti-retroviral functions. As an E3 ubiquitin ligase, TRIM5α has been shown 
to autoubiquitinate itself and produce unanchored K63-linked ubiquitin chains in vitro 
[103]. Ubiquitination is often a marker to direct substrates to particular cellular 
pathways, and we and others have observed that TRIM5α colocalizes with markers of 
the autophagy pathway [146, 164, 181]. These observations suggested a possible role 
for autophagy in TRIM5α’s restriction functions. However, we previously established 
that restriction of retroviral infection or reverse transcription by TRIM5 proteins does not 
require the autophagy effector molecules ATG5 or Beclin1 [181]. Nevertheless, it is 
possible that ubiquitination contributes to other functions of TRIM5α. Therefore, our goal 
was to delineate the role of ubiquitination in the anti-retroviral functionsTRIM5α and its 
recruitment to autophagosomes. 
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A recent study from our group determined that the E3 ubiquitin ligase function of 
TRIM5α is required for its ability to destabilize retroviral capsids [171]. TRIM5α proteins 
in which the Herpes Simplex Virus UL36 deubiquitinating enzyme (hereafter referred to 
as DUb) fused to the N-terminal RING domain of Rhesus macaque TRIM5α (DUb-
RhTRIM5α) were able to restrict HIV-1 infection, however, viral cores in complex with 
DUb-RhTRIM5α accumulated in the cytoplasm of infected cells, suggesting impaired 
destabilization of cores in the absence of competent ubiquitination [171]. Importantly, 
cells expressing a catalytically inactive version of the DUB, termed DUb*-RhTRIM5α, 
maintained the ability to both restrict infection and destabilize viral cores [171]. We 
previously observed the accumulation of DUb-RhTRIM5α-core complexes in the 
cytoplasm of infected HeLa cells [171]. These findings were recapitulated in both THP-1 
cells differentiated into macrophages and A549 cells (Fig 19-21). Importantly, from 
these studies, it was unclear if the stabilized DUb-RhTRIM5α-capsid complexes were 
being sequestered into autophagosomes for subsequent degradation. 
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Figure 19. Co-localization of DUB-Fusion Proteins and HIV-1 p24 in THP-1 Cells. 
THP-1 cells expressing the indicated Flag-tagged RhTRIM5 DUB fusion proteins were 
differentiated into macrophages and infected with HIV-1. Colocalization between Flag 
and HIV-1 p24 was assessed. Representative image are shown in (A), and a 
magnification of a DUb-RhTRIM5α image is shown in (B). 
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Figure 20.Co-localization of DUB-Fusion Proteins and HIV-1 p24 in A549 Cells. 
A549 cells expressing the indicated Flag-tagged RhTRIM5 DUB fusion proteins infected 
with HIV-1. Colocalization between Flag and HIV-1 p24 was assessed. Representative 
image are shown in (A), and a magnification of a DUb-RhTRIM5α image is shown in 
(B). 
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Figure 21. Inhibition of the Ubiquitin Ligase Function of TRIM5α Stabilizes the 
Association of RhTRIM5α with HIV-1 Viral Cores in THP-1 and A549 Cells. The 
degree of colocalization of between the different TRIM5α fusion proteins (Flag-tagged) 
and HIV-1 capsid (p24) at 6hpi in both THP-1 cells differentiated into macrophages and 
A549 cells was measured. Error bars represent SEM of at least 20 images taken for 
each cell line. Data are representative of three independent experiments. *** = p < 
0.001 by one-way ANOVA. 
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Generation of Deubiquitinase-Rhesus TRIMα Fusion Proteins 
To more directly identify the specific determinants of how TRIM5α recruits 
autophagic machinery and to determine if stabilized TRIM5α-viral core complexes are 
recruited to autophagosomes, we generated a panel of fusion proteins in which the 
catalytic domain of different deubiquitinase enzymes (DUBs), with different specificities 
for polyubiquitinated linkages, was fused to the N-terminal RING domain of Rhesus 
TRIM5α (Table 1). Our previous study utilized the HSV-1 UL36 deubiquitinating 
enzyme, which has been reported to cleave both K48 and K63-linked polyubiquitin 
chains [172, 188, 189]. The different deubiquitinase enzymes employed in the current 
study were chosen for their ability to cleave only a single type of ubiquitin linkage, even 
at high polyubiquitin concentrations in vitro [190]. In addition, each of these 
deubiquitinase-RhTRIM5α fusions was paired with a catalytically inactive 
deubiquitinase-RhTRIM5α fusion protein (denoted as "*") to control for the addition to 
the N-terminus of RhTRIM5α due to the fusion protein [171-174, 191]. 
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Table 1. Deubiquitinase (DUB)-RhTRIM5α Fusion Proteins Used in This Study. DUB enzymes were fused to the N-
terminus of Rhesus TRIM5α, in frame between the Flag tag and the RING domain.
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Deubiquitinase-RhTRIM5α Fusion Proteins Restrict HIV-1 Infection 
First, these deubiquitinase-RhTRIM5α fusions were screened for their ability to 
restrict HIV-1 infection. A549 cells stably expressing each one of the DUB-RhTRIM5α 
fusion proteins were infected with an HIV-1 reporter virus, in which infected cells appear 
green.  If ubiquitination is required for restriction, we would expect cells expressing one 
of active DUBs to be permissive to infection by the reporter virus. However, in all cases, 
both the catalytically active and inactive deubiquitinase fusion proteins retained the 
ability to restrict HIV-1 infection (Fig 22). It is worth noting that the catalytically inactive 
control for K48-specific DUB activity, OTUB1*-RhTRIM5α, was slightly more permissive 
to infection compared to the other cell lines. We believe this activity is due to protein 
folding changes that may have occurred due to the introduction of an alanine residue in 
the catalytic site of the DUB enzyme. Nevertheless, as all the fusion proteins were able 
to restrict HIV-1 infection, we concluded, from these data, that ubiquitination is not 
required for the restriction of infection by RhTRIM5α. 
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Figure 22. Deubiquitinase-RhTRIM5α Fusion Proteins Restrict HIV-1 Infection in 
A549 Cells. RhTRIM5α fusion proteins were infected with a GFP reporter HIV-1 virus 
and the proportion of infected cells (% GFP positive) was assessed 48hpi by flow 
cytometry. Data are representative of two independent experiments.  
 
K63-linked Ubiquitination Activity is Required for Restriction of Reverse 
Transcription by TRIM5α 
During restriction, TRIM5α is known to promote the disassembly of capsids prior 
to the completion of reverse transcription, although this effect is abrogated in the 
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presence of the proteasome inhibitor MG132 [156, 157]. To determine if the restriction 
of reverse transcription requires ubiquitination activity, and to specifically define what 
type of ubiquitin linkages are critical, we infected A549 cells expressing the DUB-
RhTRIM5α fusion proteins with an HIV-1 reporter virus and measured reverse 
transcription products (Figure 23). As expected, we observed minimal production of 
reverse transcription products in cells expressing RhTRIM5α, which is consistent with 
previous reports [85, 155]. In contrast, we observed an accumulation of reverse 
transcription products in cells expressing the catalytically active HSV-1 UL36 
deubiquitinase fusion protein (DUb-RhTRIM5α). This enrichment is particularly evident 
when comparing the active DUB to its catalytically inactive control, DUb*-RhTRIM5α 
(Figure 23B). In this case, reverse transcription products did not accumulate, indicating 
that ubiquitination activity by RhTRIM5α is necessary for its restriction of reverse 
transcription.  
Notably, the HSV-1 UL36 deubiquitinase enzyme demonstrates dual specificity to 
cleave both K48- and K63-linked polyubiquitin chains [172, 188, 189]. To more precisely 
define the ubiquitination linkages that are critical for the restriction of reverse 
transcription by TRIM5α, we measured reverse transcription in cells expressing K63-
specific (AMSH-LP-RhTRIM5α) or K48-specific (OTUB1-RhTRIM5α) deubiquitinase 
fusion proteins, along with their catalytically inactive controls. Significantly, we observed 
an enrichment of reverse transcription products specifically in cells expressing the 
catalytically active K63-specific deubiquitinase, AMSH-LP-RhTRIM5α, but not in cells 
expressing the K48-specific DUB (Figure 23). Furthermore, this accumulation, once 
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again, is most apparent when comparing the active K63-specific DUB fusion to its 
catalytically inactive control (Figure 23B). Importantly, we observed no difference in the 
production of reverse transcription products in cells expressing the active or inactive 
K48-specific DUB fusion proteins. From these data, we conclude that RhTRIM5α 
requires K63-specific ubiquitination activity to restrict reverse transcription.  
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Figure 23. K63-linked Ubiquitination Activity is Required for Restriction of 
Reverse Transcription by TRIM5α. Deubiquitinase-RhTRIM5α fusion proteins were 
infected with a GFP reporter HIV-1 virus and viral reverse transcription products were 
measured by quantitative real time PCR. (A) Number of reverse transcription products 
(late RT products) accumulating in the indicated cell lines. Error bars represent the 
standard deviation of technical triplicates. Data are representative of at least three 
independent experiments. (B) Values from (A) plotted as the ratio of active DUB to its 
respective catalytically inactive control.  
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Inhibition of K63-linked Ubiquitination Produces Stable Association of RhTRIM5α 
with HIV-1 Cores but Impaired Association with Autophagosome Membranes 
 Previous reports from our lab and others determined that TRIM5α cytoplasmic 
bodies often colocalize with markers of autophagy, including p62/SQSTM1, LC3b, and 
LAMP2A [146, 164, 181]. In addition, one study mapped the interactions necessary for 
TRIM5α to bind to members of the mammalian ATG8 family, of which LC3b is a 
member, and they identified a region in the Coiled-coil domain of TRIM5α that is 
necessary for this interaction [146]. This was an intriguing finding, given that, as an E3 
ubiquitin ligase, TRIM5α is autoubiquitinated, and the precise residues that are modified 
in TRIM5α have been mapped to the RING domain [103]. We previously observed that 
the ubiquitination activity of RhTRIM5α is required for its ability to destabilize viral 
cores[171], and that in the absence of ubiquitination activity, RhTRIM5α forms stable 
complexes with HIV-1 cores [171]. Therefore, we sought to determine if ubiquitination, 
and to define what type of ubiquitin linkage, is required for the stable association of 
TRIM5α with HIV-1 and for the recruitment of autophagic machinery to TRIM5α. To this 
end, we generated A549 cell lines stably expressing both YFP-tagged LC3b (YFP-LC3) 
and each one of the deubiquitinase-RhTRIM5α fusions. YFP-LC3 was utilized to mark 
autophagosome formation. LC3, a diffusely expressed cytoplasmic protein, binds to 
nascent autophagosome membranes, and therefore, punctate LC3 signal serves as 
marker of autophagosome formation. Following infection with HIV-1, we measured the 
degree of colocalization between the RhTRIM5α fusion proteins, HIV-1 p24 capsid 
protein, and/or YFP-LC3 (Figure 24-25). 
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Consistent with previous reports, we observed minimal stable association 
between RhTRIM5α and HIV-1 p24, as RhTRIM5α rapidly destabilizes viral cores 
(Figure 24-25). However, when K63-linked ubiquitination by RhTRIM5α is inhibited, as 
in the case of cells expressing DUb-RhTRIM5α and AMSH-LP-TRIM5α, we observed 
significant stable co-localization between TRIM5α the viral core, particularly when 
comparing these DUBs to their catalytically inactive controls (Figure 24-25). Importantly, 
we measured minimal stable co-localization between the K48-specific DUB fusion 
protein (OTUB1-RhTRIM5α) and HIV-1 p24, and critically there was no significant 
difference between the catalytically active and inactive fusions (Figure 25A). 
Conversely, we observed that K63-liked ubiquitination is critical for the association of 
RhTRIM5α with YFP-LC3, as both DUb-RhTRIM5α and AMSH-LP-TRIM5α showed 
minimal co-localization with LC3, in contrast to their catalytically inactive counterparts 
(Figure 25B). Collectively, these data indicate that the inhibition of K63-linked 
ubiquitination produces a stable association between RhTRIM5α and HIV-1 cores, and 
that K63-linked ubiquitination activity is critical for the association of TRIM5α with the 
autophagosome membrane marker LC3.  Notably, there was minimal triple 
colocalization between the RhTRIM5α, LC3, and p24, suggesting that autophagic 
machinery is not recruited to the sites of core disassembly. 
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Figure 24. Colocalization of DUB-Fusion Proteins, HIV-1 p24, and/or YFP-LC3 in 
A549 Cells. Representative images of A549 cells expressing the indicated Flag-tagged 
RhTRIM5α DUB fusion proteins infected with HIV-1. Colocalization between Flag, HIV-1 
p24, and/or YFP-LC3 was assessed (see Figure 24).   
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Figure 25. Inhibition of K63-linked Ubiquitination Produces Stable Association of 
RhTRIM5α with HIV-1 Cores but Impaired Association with Autophagosome 
Membranes.  A549 cells expressing deubiquitinase-RhTRIM5α fusion proteins and 
YFP-LC3 were infected with HIV-1. The degree of colocalization of between the 
different TRIM5α fusion proteins (Flag-tagged) and the HIV-1 capsid (p24) (A), or YFP-
LC3 (B) was measured. Error bars represent SEM of at least 20 images taken for each 
cell line. Data are representative of three independent experiments. *** = p < 0.001, ** = 
p < 0.01 by one-way ANOVA. 
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p62 is Critical for TRIM5α Association with Autophagosome Membranes 
p62/SQSTM1 is an autophagic adaptor protein that can bind ubiquitinated substrates 
and direct them to autophagosomes [192]. We previously determined that p62 
colocalizes with TRIM5α cytoplasmic bodies [164]. To determine if p62 is required for 
the association of TRIM5α with autophagosomes, we utilized CRISPR/Cas9 genome 
editing to target p62 or a non-targeting gRNA in A549 cells stably expressing YFP-LC3. 
These cells were subsequently transduced to stably express either RhTRIM5α or DUb*-
RhTRIM5α, given that this was the fusion protein that most potently colocalized with 
YFP-LC3 (Figure 26). We quantified the association between RhTRIM5α and LC3 and 
observed that, in the absence of p62, there is significantly less colocalization between 
YFP-LC3 and RhTRIM5α, indicating that p62 is a critical mediator of the interaction 
between RhTRIM5α and autophagosomes (Fig 26).  
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Figure 26. p62 is Critical for TRIM5α Association with Autophagosome 
Membranes.  A549 cells were depleted of p62 via CRISPR/Cas9 genome editing. 
These cells were subsequently transduced to express YFP-LC3 and the indicated DUB 
constructs (A). (B) Following infection with an HIV-1 reporter virus, the degree of 
colocalization of between the different TRIM5α fusion proteins (Flag-tagged) and YFP-
LC3 was measured. Error bars represent SEM of at least 20 images taken for each cell 
line. Data are representative of three independent experiments. *** = p < 0.001, * = p < 
0.05 by Student’s t-test. 
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CHAPTER FIVE 
DISCUSSION 
Summary of data 
TRIM5α, as other TRIM proteins, has been shown to associate with markers of 
the autophagy pathway [146, 164, 181-184], and given TRIM5α’s role as a retroviral 
restriction factor, that this association suggests a functional relationship between the 
autophagy pathway and TRIM5α. The goal of these studies was to examine the 
contributions of ubiquitination and association with autophagic effectors to TRIM5α’s 
anti-retroviral functions. 
First, we identified that the subcellular distribution of YFP-RhTRIM5α changes in 
the presence of BafA1 and MG132, with the accumulation of more cytoplasmic bodies 
of YFP-RhTRIM5α observed in the presence of autophagy inhibition compared to 
proteasome inhibition (Figure 13). We also determined that the YFP-RhTRIM5α 
cytoplasmic bodies colocalize with markers of the autophagy pathway (Figure 14). 
These observations provided the rationale to examine the role, if any, that autophagy 
plays in the restriction of retroviruses by TRIM5 proteins. For our study, we selected two 
important macroautophagy factors, Beclin1 and ATG5, which are critical for the 
nucleation and elongation of autophagosome membranes. It is worth noting that 
autophagy is a very complex cellular process involving many cellular proteins, and it is 
possible that in some cases, there may be redundant proteins that have similar effects. 
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Importantly, however, Beclin1 appears to be essential for macroautophagy [193] and 
thus was a valuable target for our assessment of autophagy in the functions of TRIM5α. 
We observed that retroviral restriction was not impacted by depletion of 
autophagic mediators by siRNA (Figure 15). This was true in the case of endogenously 
expressed huTRIM5α, which still mediated potent inhibition of N-MLV infection and 
reverse trancription following ATG5, Beclin1 or p62 knockdown. However, these studies 
do not exclude the possibility that small amounts of these mediators remaining after 
siRNA knockdown are sufficient to preserve TRIM5α-mediated restriction. We therefore 
used the CRISPR-Cas9 genome editing system to deplete cells of ATG5 or Beclin1 and 
similarly assessed N-MLV restriction by huTRIM5α (Figure 16). Similar to our 
knockdown studies (Figure 15) no relief in retroviral restriction was observed (Figure 
16D and F) in cells depleted of ATG5 or Beclin1. In addition, restriction of viral reverse 
transcription was intact following ATG5 and Beclin1 knockout (Figure 16G and H). 
Although we cannot discount the possibility that cells depleted of ATG5 or Beclin1 may 
possess alternative mechanisms of substrate degradation via autophagy, these results 
collectively demonstrate that restriction of retroviral infection and reverse transcription 
by TRIM5α is independent of ATG5 and Beclin1.  
We obtained similar results when restriction of HIV-1 by RhTRIM5α (Figure 17) 
or TRIM-Cyp (Figure 18) was examined. Restriction of HIV-1 was not impacted by 
ATG5 or Beclin1 deletion (Figure 17). We did observe that ATG5 depletion caused a 
decrease HIV-1 infection (Figure 17B), although HIV-1 restriction remained intact in 
these cells (Figure 17B). These data are in apparent contrast to the findings from a 
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recent study, which observed that the depletion of autophagic adaptor proteins 
abrogated RhTRIM5α-mediated restriction of HIV-1 [146]. One noticeable difference 
between our studies was that the Mandell et. al. study utilized primary Rhesus 
fibroblasts to examine the role of autophagic adaptors in the restriction mechanism of 
RhTRIM5α; they observed modest restriction of HIV-1 by the primary Rhesus 
fibroblasts, with minimal relief of restriction observed following the depletion of 
rhTRIM5α by siRNA [146]. Our study dissected the role of autophagy in retroviral 
restriction in the context of much more potent restriction, as observed in the restriction 
of N-MLV by huTRIM5α and HIV-1 by RhTRIM5α or TRIM-Cyp. Thus, we suspect that 
the differences between our results and the Mandell et. al. study stem from the more 
pronounced degree of restriction observed in our studies. However, we cannot exclude 
the possibility that cell type or species specific differences explain the apparent 
discordance between our observations. Furthermore, it should be noted that the 
Mandell et. al. study assessed infectivity by measuring the amount of HIV-1 p24 protein 
in the cellular lysate of infected cells, rather than through the more conventional 
approach of measuring the expression of a reporter gene expressed  upon viral 
integration. In this regard, autophagy has been implicated in regulating virus production 
[194], and therefore, the quantification of p24 in the cellular lysate, which could 
represent CA associated with the core or unincorporated CA monomers, does not 
directly reflect the restriction capabilities of TRIM5α and its relationship to autophagy. 
Although we concluded that autophagy is not required for retroviral restriction by 
TRIM5α proteins, it is possible that the association of TRIM5α proteins with autophagy 
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markers could have some other role in TRIM5α’s function. In the present study, we 
assessed the role of the ubiquitin ligase activity of RhTRIM5α on its restriction of HIV-1 
infection, reverse transcription, stable association with viral capsids, and recruitment 
with the autophagosome marker LC3. We conclude that K63-linked ubiquitin ligase 
activity of RhTRIM5α is critical for its restriction of reverse transcription and association 
with LC3. In the absence of K63-linked ubiquitination, we observed a restoration of HIV-
1 reverse transcription and the formation of stable complexes of RhTRIM5α and HIV-1. 
Finally K63-linked ubiquitination is critical for RhTRIM5α’s association with LC3. The 
results from our study are in agreement with a recent report which identified that 
TRIM5α is modified by K63-linked ubiquitination in vitro [103]. Furthermore, the same 
study assessed the contribution of ubiquitination to the restriction of reverse 
transcription by TRIM5α and found that the restriction of reverse transcription by 
TRIM5α was relieved in cells expressing a K63R mutant ubiquitin, in which the 
formation of K63-linked polyubiquitin chains is blocked [103]. One pitfall of such an 
approach is that K63-linked ubiquitination is likely important for many cellular processes, 
and expression of this ubiquitin mutant could alter cellular pathways that could have an 
indirect impact on the restriction functions of TRIM5α. Our approach, in which we fused 
different deubiquitinases to RhTRIM5α, offered the opportunity to study ubiquitination in 
the context of the assembly of TRIM5α around a capsid, as this assembly has been 
shown to be critical to the activation of the E3 ligase function of TRIM5α [102]. 
Furthermore, by pairing each DUB with a catalytically inactive control protein, we were 
able to focus our analysis on the phenotypes associated with the enzymatic activity of 
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the DUB, rather than changes that could be a consequence of adding a fusion to the N-
terminus of Rhesus TRIM5α. Finally, by including DUB enzymes with unique 
specificities for cleaving K48 or K63-linked polyubiquitin linkages, we demonstrated that 
the ubiquitin-dependent steps in restriction by TRIM5α specifically require its ability to 
generate K63-linked polyubiquitin chains. We are currently confirming the 
deubiquitinase activity of the each of the DUB-fusion proteins in in vitro studies. 
Implications of the Data: TRIM5α and the Autophagy Pathway 
Two recent studies have considered the importance of the autophagy pathway in 
facilitating core disruption by TRIM5α [146, 165]. This hypothesis is particularly 
attractive, given how K63-linked ubiquitin chains have been associated with the 
recruitment of autophagy machinery in cells [195]. In this model, TRIM5α binds to and 
forms an assembly around incoming viral cores, synthesizes K63-linked polyubiquitin 
chains [102], and recruits autophagic machinery to degrade both TRIM5α itself and its 
bound viral core [146, 165]. We showed that K63-linked ubiquitination is required for 
TRIM5α’s association with autophagosome membranes (Figure 25) and its ability to 
restrict viral reverse transcription (Figure 23). A hypothesis one can draw from these 
data is that in the absence of K63-linked ubiquitination, TRIM5α is unable to recruit 
autophagic machinery; as  result, stable complexes of TRIM5α bound to the core persist 
in the cytoplasm (Figure 24-25), allowing sufficient time for reverse transcription to 
proceed. In this case, the association with autophagosomes would be essential for the 
ability of TRIM5α to inhibit reverse transcription. However, we determined that the 
depletion of key macroautophagy factors ATG5 or Beclin1 had no impact on the ability 
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of TRIM5α to restrict reverse transcription [181]. These finding are in opposition to 
recent work highlighting the central role of specifically these two factors, along with p62, 
in restriction by TRIM5α [146]. While we disagree with this finding, it is possible that 
TRIM5α’s association with the autophagy pathway may be relevant in other contexts.  
Specifically, one recent study reported that HIV-1 infection is suppressed in 
Langerhans cells, a subset of dendritic cells found within mucosal tissues, and this 
restriction is mediated by TRIM5α [165]. In their model, Langerhans cells bind HIV-1 via 
the C-type lectin receptor Langerin, which in turn facilitates the binding of TRIM5α to the 
internalized virus [165]. Subsequently, TRIM5α directs the core complex to the 
autophagy pathway for degradation [165]. Importantly, this study found that this 
particular pathway of TRIM5α-mediated restriction was specific to Langerhans cells, as 
dendritic cells expressing a different C-type lectin receptor, DC-SIGN, were unable to 
direct the TRIM5α-virus complex  to autophagosomes for degradation [165]. However, 
our studies investigating the role of autophagy in restriction determined that restriction 
of infection by different TRIM5 proteins occurred in the absence of ATG5 or Beclin1 
(Figures 15-18) or K63-linked ubiquitination, which is critical for the association of 
TRIM5α with autophagosome membranes (Figure 22). This is supported by biochemical 
experiments which observed the spontaneous formation of TRIM5α assemblies on in 
vitro assembled capsid assemblies (Figure 8). Taken together, it is difficult to conceive 
how the formation of such an assembly, or the restriction to infection this assembly 
seems to confer, would be different in the context of Langerhans cells. However, a 
possible explanation for this apparent discord may be related to the ability of TRIM5α to 
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promote the induction of an innate signaling response upon capsid recognition [35, 
102]. In this regard, it is possible that TRIM5α signaling may occur without the formation 
of a full, restricting TRIM5α assembly around the viral core, and it is possible that, in 
Langerhans cells, induction of this innate signaling response is sufficient to suppress 
infection and could explain the decreased infection in this cell type observed by Ribeiro 
and colleagues.  
Nonetheless, identifying a restriction mechanism within Langerhans cells is 
particularly important, given their prevalence in mucosal sites, as these sites are the 
major route of transmission of HIV-1. It is also possible that the association of TRIM5α 
with autophagosomes might be more relevant for the generation of adaptive immune 
responses to the virus. In this case, autophagosomes containing TRIM5α-virus 
complexes could be fused with MHC class II containing compartments, thereby 
facilitating the delivery of antigens to MHC class II for presentation [196]. Therefore, 
association of TRIM5α with autophagosomes, in the context of infection, could be a 
means of bridging the innate and adaptive immune responses and should be an avenue 
of future investigation. 
Implications of the Data: TRIM5α and the Proteasome 
Previous reports determined that the destabilization of retroviral capsids by 
TRIM5 proteins is sensitive to proteasome inhibitors [156-158], and one implication of 
these observations is that TRIM5α utilizes proteasome machinery to destabilize 
retroviral capsids. However, this model raises important questions. Proteasomal 
degradation is generally associated with K48-linked rather than K63-linked polyubiquitin 
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linkages [126-128, 132-134]. It is possible that TRIM5α, which produces K63-linked 
polyubiquitin chains exclusively ([103] and the current study), recruits proteasomal 
machinery through a noncanonical mechanism. Two studies determined that while both 
K48- and K63-linked polyubiquitin linkages can bind to proteasomal components in vitro 
[135, 138], the processivity with which the proteasome unfolds substrates is 
dramatically reduced in substrates bearing K63-linked chains, compared to K48-linked 
chains [134]. Furthermore, individual TRIM5α proteins bind to the capsid with low 
affinity [114], and therefore, it is unclear how this low affinity interaction, coupled with 
the low processivity associated with K63-linked polyubiquitin chains, explains the 
efficient destabilization of the core that is observed during retroviral restriction by 
TRIM5α. Finally, many of the early studies investigating the role of the proteasome in 
restriction utilized proteasome inhibitors, such as MG132. However, several studies 
determined that treatment of cells with MG132 resulted in an accumulation of proteins 
bearing ubiquitin linkages of all types except for K63-linkages [142, 186], strongly 
suggesting that substrates marked with K63-linked polyubiquitin are not destined for 
proteasomal degradation. Collectively, these observations justify a reevaluation of the 
role of the proteasome in restriction by TRIM5α. 
It is worth considering how our studies with the DUB-RhTRIM5α fusion proteins, 
which essentially recapitulated the effects of MG132 observed in earlier studies [156, 
157], did so without, ostensibly, modulating the proteasome. One explanation to 
reconcile these two effects is that treatment with MG132 is known to deplete the cellular 
pool of free ubiquitin [197]. This, in turn, could potentially limit the availability of free 
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ubiquitin available for TRIM5α to complete its ubiquitin-dependent steps during 
restriction. Therefore, the effects of MG132 on restriction are likely phenotypes 
associated with side-effects of the drug itself rather than a disruption of a proteasome-
dependent step in restriction. 
The data from the current study support a model, first set forth by Barbie Ganser-
Pornillos et. al., in which the formation of an assembly of TRIM5α around a retroviral 
core is sufficient to block infection [115]. Autophagic machinery is not required for the 
restriction of retroviral infection, as both ATG5 or Beclin1 knockout cells maintained 
potent restriction of multiple retrovirsues (Figure 15-18). Furthermore, cells expressing a 
RhTRIM5α fusion protein in which K63-linked ubiquitnation is inhibited maintain potent 
restriction of HIV-1 infection (see AMSH-LP-RhTRIM5α, Figure 22) despite minimal 
association with the autophagosome membrane marker LC3 (Figure 25). Importantly, 
core destabilization, which occurs prior to reverse transcription [155] and requires the 
K63-specific ubiquitin ligase activity of TRIM5α (Figure 25) does not appear to be 
required for the restriction of infection. This suggests that TRIM5α likely evolved 
multiple mechanisms of restricting retroviral infection. An early block, which requires the 
E3 ligase activity on the RING domain of TRIM5α, promotes the destabilization of cores 
prior to the completion of reverse transcription. However, infection is still blocked 
without the E3 ligase activity, suggesting a later block to infection. This later block is 
remarkably similar to the mechanism of restriction of murine Fv1, the first characterized 
retroviral restriction factor. 
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Figure 27. Current Perspective of the Mechanism of Retroviral Restriction by TRIM5α. (left panel) During infection, 
retroviruses reverse transcribe their RNA genome (pink) into DNA (green), uncoat their capsid (blue) and traffic to the 
nucleus for integration. (right panel) TRIM5α [6] exists as diffuse protein and cytoplasmic bodies. K63-specific ubiquitin 
ligase activity of TRIM5α is critical for its association with autophagosome membrane markers and its ability to destabilize 
viral cores prior to the completion of reverse transcription. In the absence of K63-specific ubiquitin ligase activity, TRIM5α 
forms a stable association with the capsid, allowing reverse transcription to proceed, however infection is still blocked. 
This favors a model whereby the formation of a TRIM5α assembly around a capsid is sufficient to inhibit infection, while 
ubiquitin ligase activity of TRIM5α is needed to inhibit reverse transcriptio
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Fv1 inhibits retroviral infection after reverse transcription but before integration, a 
phenotype mirrored in RhTRIM5α fusions with incompetent K63-linked ubiquitin ligase 
activity (AMSH-LP-RhTRIM5α, Figure 22-23). Importantly, although TRIM5α and Fv1 
are very different at the primary sequence level, they each likely evolved independently 
in response to retroviral challenge over time [86, 198]. However, the evolution of the 
RING domain in TRIM5α proteins likely afforded TRIM5α the capacity to effectively and 
efficiently block both retroviral reverse transcription and infection. 
 Intriguingly, TRIM5-based capsid binding restriction factors have evolved at least 
twice, independently, through the retrotransposition of a Cyclophilin A pseudogene to 
replace the SPRY domain of TRIM5α [199-203]. While this retrotranspostion event 
could have occurred by chance, it is possible that the fusion of a capsid binding factor, 
such as cyclophilin A, to the TRIM motif conferred some selective advantage against 
retroviral pathogens, hence their independent evolution among different primates. In this 
regard, in a laboratory setting, fusion of cyclophilin A to a protein that is known to 
multimerize generates a capsid-binding factor that is competent to restrict HIV-1 
infection [99]. If multimerization was the only requirement to generate an efficient 
capsid-binding restriction factor, why would TRIM-based factors, specifically, arise 
repeatedly? One hypothesis is that in addition to multimerization, the TRIM motif, and 
specifically the RING domain, confers the ability to generate an antiviral signaling 
response [35], and thus was selected for over time, given the evolutionary advantages 
associated with the expression of sensors for pathogens.Upon binding to a restriction-
sensitive capsid, the ubiquitin ligase activity of TRIM5α is activated [102], and in turn 
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TRIM5α has been shown to generate free, unanchored K63-linked polyubiquitin chains 
[35]. These ubiquitin chains can subsequently bind to and promote the activation of the 
cytoplasmic kinase TAK1, which in turn promotes the activation and upregulation of AP-
1 and NFκB-dependent genes [35]. Finally, the anti-retroviral activity of TRIM5α begins 
with its binding to the retroviral capsid, and because the capsid is considered 
“genetically fragile” and is required for many aspects of the retroviral life cycle [27, 36, 
37], it is unlikely to evolve to avoid TRIM5α binding. Therefore, TRIM5α has the ability 
to efficiently couple its restriction function with the generation of an innate immune 
response, and studies to define the underlying mechanisms of restriction can help to 
enhance the activity of human TRIM5α against significant pathogens like HIV-1. 
Future Directions 
This work leaves a few important lingering questions. First, it is worth revisiting if 
proteasomes are indeed involved in the core destabilization function of TRIM5α. This 
work suggests that this destabilization occurs independently of proteasomes and 
supports a model whereby the destabilization of capsids may occur as a result of the 
dynamic movement of individual SPRY domains bound to the capsid [100]. In this 
model, the spring-like movement of the L2 region (Figure 7), which exists as a helix, 
could displace individual SPRY domains bound to the capsid and promote capsid 
disassembly [100]. However, within this model, it is unclear what role TRIM5α’s E3 
ligase activity plays, although from the current work it is clear that this ligase activity is 
required for capsid disassembly. It is possible that as the activation of the E3 ligase 
function promotes the ubiquitination of TRIM5α, this in turn imparts some 
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conformational change in the protein that facilitates the dynamic movement of the L2 
spring, and subsequently, displacement of the SPRY domain bound to the capsid. In 
another model, a recent study described how a cytoplasmic polyanion, IP6, binds to and 
stabilizes HIV-1 cores, in a manner that the authors suggest prevents spontaneous 
disassembly of the cores [204]. In this case, ubiquitination of TRIM5α bound to a capsid 
could promote the displacement of IP6 and summarily, induce the disassembly of the 
capsid. 
Furthermore, early studies describing proteasome-dependent steps in TRIM5α-
mediated restriction relied on MG132 [156-158, 162]. For example one study reported 
that during restriction, viral core components such as the RNA genome, reverse 
transcriptase and integrase proteins, and the capsid itself, are likely degraded by the 
proteasome [158]. However, given that the same study could identify no direct 
ubiquitination of core components [158], and the caveats associated with the model of 
proteasome-dependent destabilization described above, it is unclear what role, if any, 
the proteasome has in TRIM5α’s restriction functions. 
Finally it is important to consider the implications of this work on the development 
of strategies to improve the activity of human TRIM5α against HIV-1. While human 
TRIM5α is not as potent as Rhesus TRIM5α in blocking HIV-1 infection, several lines of 
evidence suggest that there are opportunities to improve its functions. For example, 
several reports have characterized SNPs in human TRIM5α that are associated with 
higher viral loads and a more rapid progression towards AIDS [205-207], suggesting 
that wild-type human TRIM5α is exerting some protective effect that is absent in 
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individuals bearing these SNPs. Furthermore, a recent study described how an 
artificially stabilized version of human TRIM5α had the ability to restrict HIV-1 infection 
to a degree comparable to that performed by Rhesus TRIM5α [208]. In this vein, 
strategies that promote the stabilization of human TRIM5α may enhance its anti-HIV-1 
activity. As a proof of this principle, it would be interesting to assess whether human 
TRIM5α fused to the K63-specific deubiquitinase enzyme, which we showed produces a 
stable complex between AMSH-LP-RhTRIM5α and HIV-1 (Figures 24-25), could impart 
improved restriction capabilities to human TRIM5α. 
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